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Abstract  
 
In humans, monooxygenases from the cytochrome P450 superfamily contribute to the biosynthesis of 
steroid hormones by catalyzing the side-chain cleavage of cholesterol and subsequent regio- and stereo-
selective hydroxylations, which determine the bioactivity of the hormones. In this work, the additional 
contribution of these steroidogenic cytochromes P450s to the metabolism of xenobiotics was established 
and their employment as highly selective and efficient biocatalysts in recombinant bacteria for the 
production of commercially relevant glucocorticoids, which are important anti-inflammatory and 
immunosuppressive drugs, was realized. 
The capability of CYP11A1, CYP11B1 and CYP11B2 to metabolize synthetic anabolic steroids, 
mineralocorticoid receptor antagonists and synthetic gestangens was demonstrated. Products were 
identified and analyzed for an alteration of their pharmacodynamic properties. 
For the biotechnological application of CYP11B1 in the production of cortisol from 11-deoxycortisol, a 
whole-cell biocatalyst was developed by reconstituting the functional CYP11B1 system, including its 
redox partners adrenodoxin reductase and adrenodoxin, in Escherichia coli. It was optimized by 
molecular evolution of CYP11B1 and by increasing the synthesis of the redox partner adrenodoxin. 
Additionally, the author contributed to the establishment of an Escherichia coli-based system for the 
application of CYP21A2 in the production of the synthetic glucocorticoid premedrol.  
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Zusammenfassung 
 
Beim Menschen tragen Monooxygenasen der Cytochrom P450 Superfamilie zur 
Steroidhormonbiosynthese bei, indem sie die Seitenkettenspaltung von Cholesterin sowie sich 
anschließende regio- und stereoselektive Hydroxylierungen katalysieren, die die Bioaktivität der 
Hormone bestimmen. In dieser Arbeit wurde die zusätzliche Beteiligung dieser Steroidhormon 
synthetisierenden Cytochrome P450 am Metabolismus von Xenobiotika festgestellt und ihre 
Anwendung als hoch selektive und effiziente Biokatalysatoren in rekombinanten Bakterien für die 
Produktion von kommerziell relevanten Glucocorticoiden, die wichtige anti-inflammatorische und 
immunsuppressive Medikamente darstellen, realisiert. 
Das Potential von CYP11A1, CYP11B1 und CYP11B2, synthetische anabole Steroide, 
Mineralocorticoidrezeptor Antagonisten und Gestagene zu metabolisieren, wurde aufgezeigt. Produkte 
wurden identifiziert und auf Veränderungen ihrer pharmakodynamischen Eigenschaften hin untersucht. 
Für die biotechnologische Anwendung von CYP11B1 bei der Produktion von Cortisol aus 11-
Desoxycortisol wurde ein Ganzzellbiokatalysator in Escherichia coli durch die Widerherstellung des 
funktionellen CYP11B1 Systems mit seinen Redoxpartnern, Adrenodoxin Reduktase und Adrenodoxin, 
entwickelt. Das System wurde durch molekulare Evolution von CYP11B1 und eine Erhöhung der 
Synthese des Redoxpartners Adrenodoxin optimiert. 
Zusätzlich wirkte die Autorin an der Etablierung eines Escherichia coli-basierten Systems für die 
Anwendung von CYP21A2 für die Produktion des synthetischen Glucocorticoids Premedrol mit. 
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1. Introduction  
1.1 Cytochromes P450 
1.1.1 Structure, nomenclature and functions  
 
Cytochromes P450 (P450, CYP) are an evolutionary highly conserved superfamily of heme thiolate 
monooxygenases. They carry a protoporphyrin IX, whose central iron is coordinated with the thiolate of 
a cysteine residue as fifth ligand. This unique structural feature of P450s leads to their eponymous 
spectral characteristic: Their reduced CO-complex exhibits an absorbance maximum at ~450 nm 
(Omura and Sato, 1962; Omura and Sato, 1964a; Omura and Sato, 1964b). Despite a high diversity of 
their primary sequences, all P450s share a conserved folding and topology due to structurally conserved 
regions (Sirim et al., 2010), which is shown exemplarily in Figure 1.1 A for the human aldosterone 
synthase, CYP11B2. In general, P450s are built of 12 main α-helices (A-L) and 4 β-sheets (Peterson and 
Graham, 1998; Sirim et al., 2010). Thereby, 4 α-helices (D, E, I and L) form a bundle constituting the 
conserved structural core, which incorporates the heme between the I- and L-helices (Mestres, 2005). 
The axial cysteine ligand of the heme is part of the conserved sequence motif FxxGx(H/R)xCxG in the 
heme ligand loop. However, several highly variable regions including 6 substrate recognition sites 
(Gotoh, 1992), which are flexible and regulate substrate binding and access to the active site, enable the 
acceptance of a large variety of substrates by the different P450 isoforms. P450 substrates include 
without limitations fatty acids, terpenes, steroids, organic solvents, alkylaryl hydrocarbon products, 
peptides and different types of drugs and pesticides (Bernhardt, 2006). 
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Fig. 1.1: Tertiary structure and nomenclature of cytochromes P450. (A) Crystal structure of human 
CYP11B2 (PDB-ID: 4DVQ) with α-helices in cyan and β-sheets in blue. The heme thiolate is shown as 
stick model with color coded atoms. The central I-helix is labelled. (B) Nomenclature of cytochromes 
P450 as proposed by Neybert et al. (1989). Primary sequence identities underlying the classification in 
families and subfamilies are indicated in brackets. 
Cytochromes P450 can be found in all domains of life and have even been discovered in viruses (Lamb 
et al., 2009; Nelson, 2013). Nevertheless, the number of P450s per organism varies between different 
species. In humans, 57 individual P450 genes exist, while the gut bacteria Escherichia coli does not 
possess any P450, but the rice plant Oryza sativa owns 457 ones (Ortiz de Montellano, 2010). Today 
more than 21,000 P450 genes are known (Nelson, 2009; Nelson, 2013). The high and still increasing 
number of P450s requires a coherent classification and nomenclature, which was introduced for the first 
time in 1987 (Nebert et al., 1987) and is based on sequence identities on protein level. The name for 
each P450 is composed of the abbreviation “CYP”, denoting the affiliation to the cytochrome P450 
superfamily, an Arabic number designating its family and a letter designating its subfamily followed by 
another Arabic number to indicate the individual P450 gene. Thereby, sequences which exhibit ≥ 40 % 
identity are grouped as a family and sequences with ≥ 55 % identity are defined as a subfamily. This 
classification is summarized for the steroid 11β-hydroxylase, CYP11B1, in Figure 1.1 B. 
P450 biodiversity regarding their primary sequence and distribution is accompanied by a large 
functional diversity. In general, P450 functions can be divided into 2 major groups. The first group 
comprises the central functions of P450s in the biosynthesis of essential and secondary metabolites, 
while the second one summarizes their key contributions to the biodegradation of xenobiotics, whereby 
they enhance polarity of the xenobiotic compound by their oxygenase activity and thus support its 
solubility and excretion. In plants, P450 activity is essential for the biosynthesis of xanthophylles, 
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structural components as lignin and suberin, UV protective flavonoids, phytohormones and flavors, but 
also a typically species-dependent variety of secondary metabolites involved in, for example, defense 
and symbiosis (Mizutani, 2012; Renault et al., 2014). Additionally, plant P450s catalyze the degradation 
of pesticides (Kahn and Durst, 2000), which makes them an interesting target for the engineering of i.e. 
herbicide resistant crop plants (Morant et al., 2003). Human P450s contribute on the one hand to the 
biosynthesis of essential compounds like steroid hormones, fatty acids, eicosanoids and fat-soluble 
vitamins. On the other hand, they are the major enzymes responsible for drug metabolism and catalyze 
approximately 75 % of the metabolism of marketed-drugs (Guengerich, 2008). Nevertheless, all 
functions trace back to the potential of P450s to activate molecular oxygen and incorporate one oxygen 
atom into their respective substrate, while the other oxygen atom is reduced to water. This is enabled by 
a common catalytic mechanism catalyzed at the heme iron. 
1.1.2 Reaction mechanism, redox systems and spectroscopic characteristics 
 
The P450 catalysis exhibits a complex reaction mechanism, which includes according to current, general 
acceptance the 8 intermediates illustrated in Figure 1.2 A (Denisov et al., 2005). Some intermediate 
states represent, however, hardly measurable radicals. In the resting state of the enzyme, the ferric heme 
iron (Fe3+) is bound to a water molecule as sixth ligand (1). Substrate binding (RH) perturbs the water 
coordination (2). Reduction by the first electron leads to the transition of the heme iron to the ferrous 
state (Fe2+, 3). Upon O2 binding the oxy-P450 complex is formed (4), which represents the last relatively 
stable intermediate in the cycle. A reduction of the distal oxygen by the second electron initiates the 
formation of a peroxo-ferric intermediate (5a), also termed compound 0, and subsequent protonation 
forms a hydroperoxy-ferric intermediate (5b). After a second protonation of the distal oxygen, 
heterolysis of the O-O bond occurs yielding the formation of water and compound I, which is supposed 
to be a ferryl-oxo-π-cation radical (6). Compound I can oxygenate the substrate (ROH, 7), whose 
dissociation restores the initial water-bound resting state of the enzyme (1). A common signature amino 
acid sequence (A/G)-Gx(E/D)T in the central kink of the I-helix carrying a highly conserved threonine 
together with a preceding acidic residue (acid/alcohol pair) thereby emerged as crucial for an efficient 
proton delivery, heterolytic O-O scission and the formation of compound I (Imai et al., 1989; Martinis et 
al., 1989; Kimata et al., 1995; Vidakovic et al., 1998). Nevertheless, a complete fulfillment of the cycle 
is not obligate. The peroxo-ferric intermediate (5a) can also intervene with proton independent catalysis, 
which has recently been demonstrated for the lyase activity of the mammalian CYP17A1 (Gregory et 
al., 2013) and for the oxidation of a hydroxyl to the corresponding ketone by the bacterial CYP106A1 
(Kiss et al., 2015a). Additionally, 3 major side reactions or shunt pathways can abort the mechanism 
prior to product formation and convert the enzyme back to the ferric state, which is also indicated in 
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Figure 1.2 A. Besides simple carbon hydroxylations, the mechanism of oxygen activation allows 
additional versatile reactions, which include heteroatom oxygenation, aromatic hydroxylations, C-C 
bond cleavage and heteroatom dealkylation, epoxidation, oxidative deamination and dehalogenation. 
Furthermore, uncommon P450 reactions are reductions, desaturations, oxidative ester cleavage, ring 
formation and expansion, dehydration, rearrangements and isomerizations (Sono et al., 1996; 
Guengerich and Munro, 2013). 
As described above, P450 oxygenase activity requires 2 electrons per introduction of one oxygen atom 
into the substrate. Electrons are obtained from NAD(P)H via specific electron transport chains which are 
constituted of additional proteins. Depending on the composition of these chains, P450 redox systems 
can be classified into 10 classes (Hannemann et al., 2007). The 2 classes occurring in humans are shown 
schematically in Figure 1.2 B and C. Their composition depends on the subcellular localization of the 
P450 system. Mitochondrial P450s are associated with the inner mitochondrial matrix and need 2 
additional proteins, which obtain electrons from NADPH: The NADPH-dependent, FAD-containing 
ferredoxin reductase (FdR) and a [2Fe-2S]-ferredoxin (Fdx), which is a soluble protein of the 
mitochondrial matrix and sequentially transfers electrons from the FdR to the P450. This system is 
called class I system and also occurs in bacteria, whereby all 3 proteins are soluble in the cytoplasm. 
The other group of human P450s is located in the membrane of the endoplasmic reticulum on the 
cytoplasmic side and depends on a class II redox system. These microsomal P450s are supported by a 
single membrane-bound electron transfer partner, cytochrome P450 reductase (CPR), which directly 
transfers electrons to the P450 via its FAD and FMN centers. 
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Fig. 1.2: Catalytic cycle of cytochromes P450 and electron transport systems. (A) – Catalytic cycle 
of cytochromes P450 according to (Denisov et al., 2005) with schematic representation of events leading 
to substrate hydroxylation at the heme iron. Numbers refer to the intermediate states described in the 
text. Grey arrows indicate the autoxidation shunt (I), peroxide shunt (II) and oxidase shunt (III). (B) 
Schematic organization of the mitochondrial class I P450 system. FdR = NADPH-dependent ferredoxin 
reductase, Fdx = ferredoxin, P450 = cytochrome P450. (C) Schematic organization of the microsomal 
class II P450 system, CPR = cytochrome P450 reductase, ER = endoplasmic reticulum. Prosthetic 
groups of each protein are indicated in italics. B and C were constructed according to (Hannemann et al., 
2007) with modifications. 
The absorbance spectrum of cytochromes P450 is sensitive to the oxidation state of the central heme 
iron as well as to the nature and concentration of the axial sixth ligand due to the effects of ligand 
binding on the spin state equilibrium of the heme iron. These spectroscopic characteristics make UV/vis 
spectroscopy an attractive tool for the quantification of P450s and the determination of ligand affinity. 
As already introduced, a characteristic absorbance maximum can be detected at ~450 nm for the reduced 
and CO-bound P450 complex due to the unique presence of a heme thiolate formed with a totally 
conserved cysteine. The respective heme iron coordination and spectrum are demonstrated in Figure 1.3 
A and B. This spectrum is not just a qualitative verification for all P450s, but can also serve for the 
determination of P450 concentration by the specific molar extinction coefficient ε450nm=91 mM
-1cm-1 
(Omura and Sato, 1964a; Omura and Sato, 1964b). The ferric P450 heme iron can exist with 2 different 
total spin angular momentums (S), which are either the high spin state of S=5/2 or the low spin state of 
S=1/2. Substrate-free P450 in its hexa-coordinated form with a water molecule as axial sixth ligand 
predominantly occurs in the low spin ferric state and therefore exhibits an absorbance maximum at ~417 
nm (Figure 1.3 A2). Substrate binding and consecutive displacement of the axial water leads to a 
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(partial) transition of the spin state to the high spin form, which shifts the absorbance maximum to ~390 
nm (Figure 1.3 A3). In contrast, the binding of a strong-field, in general nitrogen-containing, ligand 
stabilizes the low spin form and shifts the absorbance maximum to ~425 nm (Figure 1.3 A4) 
(Schenkman et al., 1967; Schenkman, 1970; Sligar, 1976; Schenkman et al., 1981; Gibson and 
Tamburini, 1984). Most of these ligands represent P450 inhibitors as they stabilize a low reduction 
potential and prevent oxygen binding, but also several low spin shift inducing, nitrogen-containing P450 
substrates have been described (Locuson et al., 2007). The effect of ligand binding on spin state and 
absorbance spectrum can be used for the spectroscopic determination of dissociation constants (Kd). 
Therefore, difference spectra of the ligand-bound P450 deducting the spectrum of the ligand-free P450 
are measured during the titration of the ligand. Binding of a putative substrate and transition to the high 
spin state lead to the formation of a type I-difference spectrum (Figure 1.3 C), while binding of a strong 
low spin-stabilizing ligand leads to the formation of a type II-difference spectrum ( Figure 1.3 D) 
(Schenkman and Jansson, 2006). A Kd can be derived from the spectra by regression of the absorbance 
shift (∆Amax-min) as a function of the ligand concentration. Additionally, a rare reverse type I-difference 
spectrum with a minimum at ~390 nm and a maximum at ~420 nm can be observed, when a high 
amount of high spin P450 is converted into the low spin state by the particular ligand (Schenkman et al., 
1972). However, it has to be noted that a ligand-induced high spin shift and P450 catalysis do not 
necessary depend on each other. Several substrates have been demonstrated to be converted without any 
observation of spectral changes (Girhard et al., 2010; Schmitz et al., 2014; Kiss et al., 2015b), while 
some type I-ligands are not converted (Schmitz et al., 2012; Khatri et al., 2013). Besides ligand-binding, 
the spin state equilibrium of the heme iron can be influenced by temperature (Sligar, 1976), redox 
partner interaction (Schiffler et al., 2001), and heme deformation (Groenhof, 2007).   
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Fig 1.3: Heme iron coordination and resulting spectroscopic changes of the P450-ligand complex. 
(A) Schematic representation of the heme iron coordination by CO with preceding reduction (1), by 
water (2), upon substrate (RH) binding and displacement of the water (3) and by a nitrogen-containing 
ligand (RNR) (4). (B) Difference spectrum of the CO-bound reduced P450 complex (1) deducting the 
reduced P450 state with the eponymous maximum at 450 nm. (C) Type I-difference spectrum of the 
substrate-bound P450 complex (3) deducting the substrate-free water-bound form (2) with a maximum 
at ~385-390 nm and a minimum at ~420 nm resulting from a high spin shift of the heme iron. (D) Type 
II-difference spectrum of the P450 in complex with a nitrogen-containing ligand (4) deducting the 
ligand-free form (2) with a maximum at ~425-435 nm and a minimum at ~405-412 nm resulting from a 
low spin shift of the heme iron. 
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1.2 Functions of human cytochromes P450 
In all biological kingdoms P450 functions can be divided into 2 major groups, which are the 
biodegradation of xenobiotics and the biosynthesis of essential compounds and secondary metabolites. 
Correspondingly, human P450s are traditionally categorized based on their major substrate classes and 
their critical role in the biotransformation of these substrates (Guengerich et al., 2005; Guengerich, 
2008; Guengerich and Cheng, 2011). These include, on the one hand, xenobiotics and, on the other 
hand, endogenous compounds like sterols, fatty acids, eicosanoids and vitamins. The following sections 
will introduce the role and function of human P450s in, firstly, xenobiotic metabolism and, secondly, 
steroid hormone biosynthesis, which are central to the scientific contribution of this work. 
1.2.1 Xenobiotic metabolism 
The human body is permanently exposed to xenobiotic substances, which enter the body via its inner 
and outer surfaces, like the skin, gastrointestinal tract and lung, with the food, aerosols or cosmetic 
products among others. These agents include toxicants and carcinogens. Additionally, marketed 
pharmaceuticals are consumed intendedly for cure and prevention, as well as non-approved drugs for 
abuse. The application of a xenobiotic is followed by its resorption and distribution over the body with 
the blood flow. This allows the execution of its biological effects at its receptor sites, which might be 
desired or adverse. Furthermore, the substance can accumulate and be stored in particular tissues or 
compartments. All living organisms, however, own enzymatic systems for the biotransformation of 
xenobiotics to accelerate its clearance by increasing the polarity and solubility of the mainly 
hydrophobic xenobiotics. In humans, clearance takes place as renal and biliary excretion and in minor 
rates by intestinal secretion (Figure 1.4). Biotransformations of xenobiotics are divided into the phase-I 
and phase-II metabolism. During the phase-I metabolism functional groups are introduced or exposed. 
The most important reactions, thereby, are cytochrome P450-catalyzed oxidations. Other enzymes that 
contribute to the oxidative reactions of the phase-I metabolism are alcohol and aldehyde 
dehydrogenases, xanthine oxidase, amino oxidases and flavin-containing monooxygenases. Further 
reactions are carried out by reductases, esterases and epoxide hydrolases. Phase-II metabolism 
subsequently leads to the conjugation of functional groups with polar or negatively charged endogenous 
molecules. The most important conjugations are glucuronidation, sulfonation, methylation, acetylation 
and conjugation with amino acids and glutathione (Hofmann et al., 2013).  
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Fig 1.4: Overview of pharmacokinetics and pharmacodynamics with indication of P450 
contribution. After its application a xenobiotic is resorbed and distributed, in general via the blood, to 
various tissues, where it can be stored and execute its biological functions, prior to its excretion. 
Chemical modifications of the xenobiotic (biotransformations) carried out by cytochromes P450s among 
other enzymes facilitate its excretion and modulate its bioactivity. Figure was adopted from (Hofmann et 
al., 2013) with modifications. 
From the 18 human P450 families only the families 1, 2 and 3 contribute to the biotransformation of 
xenobiotics (Zanger and Schwab, 2013). They are expressed in the liver and represent microsomal 
P450s. Among them, only 4, which are CYP3A4, CYP2C9, CYP2C19 and CYP2D6, catalyze ~95 % of 
all known P450 reactions in the metabolism of marketed drugs (Guengerich, 2008). P450 oxygenation 
supports xenobiotic clearance by increasing the solubility and delivery of conjugation sites for the 
phase-II metabolism. Nevertheless, their activity can also greatly alter the biological activity of the 
parent compound by modifying toxic effects or bioactivation to reactive products (Nelson, 1982; 
Guengerich et al., 1985), which might lead to desired but also dangerous adverse effects. Therefore, the 
American Food and Drug Administration (FDA) released a guideline for the safety testing of drug 
metabolites (Food and Drug Administration, 2008). Metabolites, which are formed at greater than 10 % 
of the parent compound are recommended to be safety assessed by general toxicity, genotoxicity, 
embryo-fetal development toxicity studies and carcinogenicity studies. However, one can also profit 
from the concept of the bioactivation of a parent compound by the application of prodrugs, which are 
only activated after resorption during their distribution over the body when they are metabolized by the 
respective enzymes. Cytochromes P450 are greatly responsible for inter- and intra-individual variability 
in drug pharmacokinetics and response (Zanger and Schwab, 2013). P450 metabolism varies due to 
genetic polymorphisms, which alter enzymatic activity, the copy number of the gene or introduce 
promoter variants. This enables a classification of human populations into poor, intermediate, excessive 
and ultra-rapid metabolizers for particular drugs, which is reported to have clinical significance 
regarding adverse effects, drug efficacy and, thus, dose requirements. Moreover, P450 expression 
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changes in response to xenobiotics, hormone levels, disease state, sex and age of an individual. External 
factors like nutrition and the administration of other drugs can influence metabolism by P450 inhibition 
or induction. All these factors and their specific influence on the CYP1, 2 and 3 families were recently 
reviewed by (Zanger and Schwab, 2013). The characterization of drug-metabolizing P450s and the 
identification and biological characterization of emerging metabolites are, thus, challenging, but crucial 
tasks to ensure the design of safe and efficient pharmaceuticals.  
1.2.2 Steroid hormone biosynthesis 
Steroid hormones are synthesized from the membrane lipid cholesterol in the adrenal cortex and gonads 
by the P450s from the mitochondrial CYP11 family and the microsomal families 17, 19 and 21 together 
with 2 hydroxy steroid dehydrogenases (Bernhardt and Waterman, 2007; Miller and Auchus, 2011). 
Figure 1.4 gives an overview of the reaction cascades leading to the formation of the three main classes 
of steroid hormones, which are mineralocorticoids, glucocorticoids and sex hormones. They exert their 
diverse functions via classic cytosolic steroid hormone receptors. These are hormone-activated 
transcription factors, which activate the transcription of specific target genes upon ligand binding. Table 
1.1 summarizes the central functions for all steroid hormone classes, the tissue/compartment of their 
biosynthesis and the major system responsible for the regulation of biosynthesis. The enzymatic 
properties of the different P450s contributing to their synthesis will be introduced in the following. 
Table 1.1: Functions and biosynthesis of steroid hormones. For each class of steroid hormones the 
most important representative, the central function, localization and regulation of the biosynthesis are 
indicated (Norman and Litwack, 1997a; Norman and Litwack, 1997b; Norman and Litwack, 1997c; 
Norman and Litwack, 1997d; Norman and Litwack, 1997e). 
   Biosynthesis 
Class Representative Function Localization Regulation 
Mineralocorticoids Aldosterone Water/electrolyte 
homeostasis 
Adrenal 
zona glomerulosa 
Hypothalamic-
pituitary-adrenal axis 
Glucocorticoids Cortisol Energy mobilization 
Immune response 
Adrenal 
zona fasciculata 
Renin-angiotensin-
system 
Sex hormones  Sexual characteristics:  Hypothalamic-
pituitary-gonadal axis Androgens Testosterone Male  Testis 
Estrogens Estrone Female  
Menstrual cycle 
Ovaries 
Gestagens Progesterone Gestation Corpus luteum 
Placenta 
Hypothalamic-
pituitary-gonadal axis 
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CYP11A1 (cholesterol side-chain cleavage enzyme) catalyzes the initial and enzymatically rate-limiting 
step of steroid hormone biosynthesis in all steroidogenic tissues, which is the side-chain cleavage of 
cholesterol yielding pregnenolone, the common precursor of all steroid hormones. The side-chain 
cleavage requires six electrons and three molecules of O2 and proceeds via the two intermediates 22(R)-
OH-cholesterol and 20,22-diOH-cholesterol (Boyd et al., 1971; Katagiri et al., 1976; Chung et al., 
1986). Cholesterol is delivered for this reaction by the steroidogenic acute regulatory (StAR) protein 
from the outer to the inner mitochondrial membrane. This transport step represents the overall rate-
limiting step of steroidogenesis. CYP11A1 is also capable to catalyze the side-chain cleavage of other 
sterols, like 7-dehydrocholesterol, lumisterol, the fungal sterol ergosterol, the plant sterols campesterol 
and β-sitosterol and hydroxy-sterols like 24-OH-cholesterol, 25-OH-cholesterol and 27-OH-cholesterol. 
Additionally, CYP11A1 accepts vitamin D-type substrates for hydroxylation, but not for side-chain 
cleavage. Vitamin D3 can be hydroxylated in positions 17, 20, 22, 23 by CYP11A1 and vitamin D2 in 
positions 1, 17 and 20. The present knowledge about the CYP11A1 reaction repertoire was recently 
reviewed by (Slominski et al., 2015). The additional activities towards vitamin D and plant compounds 
seem physiologically important as CYP11A1 is also expressed in tissues different than the classical 
steroidogenic ones including the gastrointestinal tract (Guo et al., 2003), where it comes into contact 
with nourishment, and the skin, where vitamin D is generated from 7-dehydrocholsterol by UV energy 
and temperature-dependent isomerization. Moreover, the steroids androstenedione, 
dehydroepiandrosterone (DHEA), 11-deoxycorticosterone (DOC) and testosterone can undergo 
hydroxylation by CYP11A1 in the positions 2β, 6β and 16β (Mosa et al., 2015).  
Human CYP17A1 (steroid 17α-hydroxylase/17,20-lyase) possesses a steroid 17α-hydroxylase and 17,20 
carbon-carbon lyase activity and is, in this way, an important branch point for the biosynthesis of 
glucocorticoids and sex hormones. It synthesizes the glucocorticoid precursor 17-OH-progesterone in 
the adrenal zona fasciculata and the testosterone and estrogen precursors DHEA and androstenedione 
from progesterone and pregnenolone in the adrenal zona reticularis and other steroidogenic tissues. 
CYP17A1 carbon-carbon lyase activity thereby depends on the presence of the allosteric effector 
cytochrome b5, which is absent in the adrenal zona fasciculata (Katagiri et al., 1995; Auchus and Miller, 
1999; Pandey and Miller, 2005; Bernhardt and Waterman, 2007). Furthermore, CYP17A1 has a 
preference regarding the C-C scission for the 3-OH-∆5 steroid 17-OH-pregnenolone over the 3-keto-∆4 
steroid 17-OH-progesterone due to differential hydrogen bonding and specific allosteric effects of 
cytochrome b5 (Gregory et al., 2013; Khatri et al., 2014). For progesterone an additional 16α-
hydroxylase activity was demonstrated (Petrunak et al., 2014). Moreover, a role of CYP17A1 in the 
metabolism of sulfonated steroids was proposed, as bovine CYP17A1 was shown to convert 
pregnenolone sulfate to its 17-OH derivative, without a subsequent lyase reaction (Neunzig et al., 2014).    
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Following androgen biosynthesis by CYP17A1, CYP19A1 (aromatase) synthesizes estrogens from the 
androgen precursors in both, men and women, but in significantly higher levels in women. Synthesis 
takes place in testis or ovaries and several extra gonadal tissues like skin, brain and adipose tissues 
(Simpson and Davis, 2001). Testosterone and androstenedione are converted to estradiol and estrone, 
respectively, by removal of the C19 carbon and aromatization of the A-ring. 16α-OH-testosterone 
represents an alternative substrate for this reaction. The aromatization requires three mols of O2 and 
three mols of NADPH (Thompson and Siiteri, 1974a; Thompson and Siiteri, 1974b) and was shown to 
be a 3-step reaction which goes through 19-hydroxy and 19-aldehyde intermediates followed by a C10-
C19 lyase reaction leading to the A-ring aromatization (Akhtar and Skinner, 1968; Braselton et al., 1974; 
Akhtar et al., 1982; Ghosh et al., 2009). Aromatization is accompanied by stereospecific hydrogen 
eliminations in 1β and 2β positions (Townsley and Brodie, 1968; Fishman et al., 1969).      
CYP21A2 (steroid 21-hydroxylase) produces the precursors for mineralo- and glucocorticoid 
biosynthesis in the adrenal by catalyzing the 21-hydroxylation of progesterone and 17-OH-progesterone 
yielding DOC and 11-deoxycortisol (Reichstein’s substance S, RSS), respectively. This steroid 21-
hydroxlyation was the first P450-mediated reaction discovered in adrenal microsomes in 1963 to be 
involved in steroid biosynthesis (Estabrook et al., 1963). For bovine CYP21 a further 20β-oxidase 
activity for 20β-hydroxy-C21-steroids has been demonstrated (Tsubaki et al., 1998).  
The final steps of gluco- and mineralocorticoid biosynthesis are subsequently catalyzed by the 2 
CYP11B subfamily members, CYP11B1 (steroid 11β-hydroxylase) and CYP11B2 (aldosterone 
synthase), which exhibit overlapping but distinct reaction repertoires despite a primary sequence identity 
of 93 % and the localization of all diverging residues outside the active site (Strushkevich et al., 2013). 
The current knowledge about the occurrence, evolution and the contribution of the enzymes from the 
CYP11B subfamily to the biosynthesis of steroid hormones in different species, as well as their 
regulation at different levels (gene expression, cellular regulation, regulation on the level of proteins) 
was reviewed in detail by the author of this thesis in a publication, which is printed in chapter 2.5 
(Schiffer et al. 2015, Review article). CYP11B1 catalyzes the 11β-hydroxylation of RSS in the adrenal 
zona fasciculata and thereby produces cortisol, the major human glucocorticoid (Kawamoto et al., 
1990b; Denner et al., 1995; Mulatero et al., 1998; Schiffer et al., 2015). It is also expressed in small 
quantities in the zona reticularis, but due to the low expression of the 3β-hydroxy steroid dehydrogenase 
this zone mainly produces DHEA (Gell et al., 1998). DOC also represents an efficient substrate for the 
11β-hydroxylation by CYP11B1. Besides this, minor activities as 18- and 19-hydroxylase for DOC 
could be ascribed to CYP11B1 (Kawamoto et al., 1990b; Mulatero et al., 1998). CYP11B2 completes 
the biosynthesis of the major human mineralocorticoid aldosterone from DOC by a 3-step reaction 
sequence consisting of 11β- and 18-hydroxylation and an oxidation to the 18-aldehyde (Kawamoto et 
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al., 1990a; Mulatero et al., 1998; Hobler et al., 2012). The ability to perform an additional 18-oxidation 
distinguishes it from CYP11B1. The formation and secretion of aldosterone exclusively takes place in 
the adrenal zona glomerulosa, which is ensured by the restriction of CYP11B2 expression to that zone in 
combination with the absence of CYP17A1 (Rainey, 1999). Additionally, CYP11B2 can catalyze an 
analogous 3-step reaction sequence on RSS yielding 18-oxo-cortisol (Mulatero et al., 1998; Freel et al., 
2004) and shows a minor activity as 19-hydroxylase of DOC (Hobler et al., 2012). Both CYP11B 
isoforms have also been demonstrated to contribute to the metabolism of progesterone and the two 
androgens testosterone and androstenedione by forming the respective 11β-OH derivatives 
(Strushkevich et al., 2013; Swart et al., 2013).  
In summary, steroidogenic P450s have been characterized to conduct highly stereo- and regio-selective 
hydroxylations and C-C cleavages with substrate specificities limited to particular steroid intermediates. 
This enables a straight-forward synthesis of different classes of steroid hormones, which is essential as 
P450-mediated functionalization is crucial for an efficient but specific activation of the respective target 
receptors. Only recently, the findings that CYP11B1, CYP11B2 and CYP21A2 may contribute to the 
metabolism of the synthetic anabolic androgenic steroid (AAS) metandienone (Zöllner et al., 2010b; 
Parr et al., 2012) and that CYP11B1 putatively catalyzes the bioactivation of an insecticide metabolite 
(Lund and Lund, 1995) began to change our perspective on the metabolic potential of steroid hormone 
synthesizing P450s, which will further be elucidated in one part of this work. 
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Fig. 1.4: Human steroid hormone biosynthesis. Reaction cascades catalyzed by cytochromes P450 
and hydroxy steroid dehydrogenases lead to the formation of mineralocorticoids, glucocorticoids and 
sex hormones. Oxidative changes introduced to the steran scaffold are highlighted by color together with 
the respective P450 for each step. Subcellular localization of the reaction steps is indicated by the arrow 
style. Note that P450 expression and activity and, thus, formation of the different steroid hormones are 
tissue and compartment specific. 
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1.3 Biotechnological potential and limitations 
Biocatalysis is defined as the application of enzymes and microbes in synthetic chemistry for purposes 
they have not evolved for (Bornscheuer et al., 2012). It respects in particular the principles of Green 
Chemistry (Anastas and Warner, 1998) by its environmental and economic advantages. Biocatalysts 
grow from renewable feedstocks, are non-toxic and biodegradable. They enable catalysis at ambient 
temperature, atmospheric pressure and neutral pH and their selectivity facilitates down-stream 
processing.   
Cytochromes P450 own a unique capability to activate molecular oxygen for stereo- and regio-selective 
oxidations of inactive C-H bonds. This catalytic potential turns them into promising catalysts for 
biotechnological applications in the industrial synthesis of fine chemicals and chiral pharmaceuticals. 
They represent attractive alternatives to classical chemical synthesis, which often requires harsh reaction 
conditions and lacks selectivity in oxy functionalization (Loughlin, 2000; Labinger, 2004). Nevertheless, 
the presence and stereochemistry of functional groups, i.e. hydroxylations, are important determinants 
for the bioactivity of pharmaceuticals and the introduction of new stereo-centers with oxy functions 
opens the paths for further chemical modifications. Interesting reactions hereby are the formation of 
halogen, azide or amino derivatives (Zhang et al., 2012) as well as esterification, which can 
subsequently serve for the inversion of the stereo-center by hydrolysis (Tapolcsányi et al., 2004). This 
selectivity can be enabled by P450 application. Furthermore, the employment of human drug-
metabolizing P450s in the production of metabolites for toxicity studies is of great interest (Zöllner et 
al., 2010a). 
The minimum requirements for a putative industrial application, which are defined as a space-time-yield 
of 0.1 g*L-1*h-1 and a final product concentration of 1 g*L-1 for fine chemicals and 0.001 g*L-1*h-1 and a 
final product concentration of 0.1 g*L-1 for pharmaceuticals (Straathof et al., 2002; Julsing et al., 2008), 
are to date, however, only hardly met by P450 systems due to their complex multicomponent nature and 
the need for the costly co-factor NAD(P)H. Examples of industrial application of P450s are the 
biotransformation of RSS to cortisol with fungi of the species Curvularia (i.e., Curvularia lunata), 
which possess an endogenous steroid 11β-hydroxylase (P450lun) (Petzoldt et al., 1982) and the de novo 
synthesis of artemisinic acid, a precursor of the anti-malaria drug artemisinin, with recombinant 
Saccharomyces cerevisiae including CYP71AV1 from Artemisia annua (Ro et al., 2006; Paddon et al., 
2013). For P450s, the usage of whole-cell biocatalysts expressing the complete functional redox system 
is thereby preferable over the use of purified enzymes (Schmid et al., 2001). The intracellular 
environment provides a stabilizing effect for the enzymes and NAD(P)H can be obtained and 
regenerated by the cellular metabolism. For the establishment of a whole-cell system, one can either 
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make use of an organism’s endogenous P450 systems, which might require great screening efforts to 
select a suitable strain, or follow a recombinant approach by expressing the P450 system of interest in an 
appropriate microorganism. The second strategy provides the advantages that the host organism can be 
chosen with regard to the particular P450 and reaction and that the sequences of the P450 and its redox 
partners are directly available for enzyme engineering. Nevertheless, recombinant expression implies the 
knowledge of a P450 with the respective activity and the availability of its gene or cDNA sequence. 
This requires basic preliminary work in the fields of substrate screening and genome mining to establish 
characterized libraries of P450 biocatalysts.      
Subsequent to the establishment of a P450 system, its improvement towards a stable, selective and 
productive catalyst in large scale processes faces a variety of challenges. Limitations can be approached 
on different levels by engineering of the enzyme, the reaction conditions and the host cell, which is 
summarized in Table 1.2 including methodical approaches. Optimization can be completed by process 
engineering, which considers down-stream process issues (Julsing et al., 2008) and is not further 
relevant for this work. Enzyme engineering can optimize, on the one hand, the recombinant expression 
and stability by sequence modifications (Gillam, 2008), which is especially important for the application 
of membrane-associated mammalian and plant P450s, and, on the other hand, the activity and selectivity 
of the P450. Optimizing the latter properties is traditionally performed by either side-directed 
mutagenesis (SDM), a rational approach relying on established structure-function relations, or by 
molecular evolution (ME) consisting of several rounds of random mutagenesis and selection for the 
desired properties (Bloom et al., 2005). The first approach is, however, hampered by the limited 
availability and quality of 3D structures of P450s. This is especially valid for mammalian and plant 
P450s, which have a tremendous biotechnological potential due to their outstanding selectivity and 
diverse functions in secondary metabolism, but are demanding to express, to purify and to crystalize. 
Where limited structure-function information is available, molecular evolution represents the tool of 
choice. Its close-to-nature principal thereby opens up the discovery of synergistic mutational effects. 
The greatest challenge is the establishment of a sensitive screening system with a high throughput to 
select mutants with the desired properties in a time- and cost-efficient way (Kuchner and Arnold, 1997). 
Ideally, colorimetric and fluorimetric detection methods are established (Gillam, 2007; O'Reilly et al., 
2011). The screening effort can further be reduced by the design of smart mutant libraries via the 
incorporation of reduced amino acid alphabets, the use of codon degeneracies or the stringent definition 
of randomization sites (Acevedo-Rocha et al., 2015).    
Electron delivery from NAD(P)H by electron transfer proteins is essential for P450 catalysis and is 
therefore introduced as an extra level of engineering in Table 1.2 for the optimization of P450 
application. The nature of redox partners, which are co-expressed with a particular P450, as well as their 
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final ratio have to be considered for optimal activity. Due to the high conservation of the interaction 
domains (Sirim et al., 2010; Gricman et al., 2014), the employment of heterologous redox partners is 
feasible and eukaryotic redox systems can be replaced by bacterial systems (Ringle et al., 2013) as well 
as class II systems by class I systems (Pechurskaya et al., 2007). Another highly sophisticated, but to 
date not yet practicable approach, is the construction of artificial self-sufficient P450s by fusion of the 
P450 with a reductase domain (Munro et al., 2007; Gillam, 2008; Sadeghi and Gilardi, 2013). 
The third level of engineering targets the host cell, whose physiology is crucial for protein synthesis and 
NAD(P)H supply and can be modulated by metabolic engineering or recombinant co-expression of 
proteins. Popular host organisms are the yeast species Saccharomyces cerevisiae, Schizosaccharomyces 
pombe and Pichia pastoris and bacteria like Pseudomonas putida and Bacillus subtilis (Hanlon et al., 
2007). The currently favored organism is, however, Escherichia coli (E. coli), which provides well-
established molecular biology techniques and the advantage of the absence of endogenous P450s.  
Engineering on the level of the reaction aims at stabilizing an efficient and continuous production. Cell 
growth, protein synthesis and the P450 reaction reduce nutrient and oxygen levels in the culture and 
alter the pH, which can be controlled by fermentation with feed optimization. Such approaches have 
been demonstrated to enhance P450 expression by up to 10-fold (Vail et al., 2005). Substrate solubility 
can represent another limiting factor, especially for the production of pharmaceutical steroids, which can 
be overcome by the addition of organic solvents or other solubilizing agents (Donova and Egorova, 
2012). 
Due to their catalytic potential and selectivity, P450s conclusively represent promising candidates for an 
economically and ecologically sustainable production of chiral compounds, but still require diverse 
optimization efforts to be established as stable and efficient biocatalysts, which can be achieved with 
consideration of all levels introduced above.  
 
 
 
 
 
 
1. Introduction 
 
20 
 
Table 1.2: Levels of engineering for the optimization of P450 whole-cell biocatalysts. Levels were 
divided as proposed previously (Julsing et al., 2008) with the addition of “Redox system” as 
independent level. Limitations that can be targeted on each level are summarized together with 
respective methodical approaches (Urlacher and Eiben, 2006; O'Reilly et al., 2011; Bernhardt and 
Urlacher, 2014). Limitations and strategies targeted in this work are highlighted in blue. SDM: side-
directed mutagenesis; ME: molecular evolution. 
 
Level of 
engineering 
Targeted limitations Methodical approaches 
 
 
P450 
Expression and stability 
 
Sequence truncation or replacement, codon 
usage 
Activity 
Selectivity 
Substrate specificity 
Un-coupling1 
 
SDM, ME, gene shuffling 
 
Redox system 
Expression ratio 
 
Alteration of gene copy number or promoter 
Interaction/electron transfer Exchange or fusion of redox partners  
SDM, ME 
 
 
Reaction 
Substrate solubility  
 
Substrate availability 
Co-solvents, 2-phase-systems  
 
Membrane permeabilization 
Product toxicity In-situ product removal 
Medium-catalyst interaction 
NADPH availability 
Modification of reaction medium    
Temperature, pH, O2, feeding control by     
fermentation 
 
 
 
Host cell 
NADPH availability 
 
 
Use of non-growing cells 
Metabolic engineering  
Co-expression: regenerating systems 
Protein synthesis 
 
Modifications of the expression system    
(promoter, RNA polymerase activity) 
Enhancement of heme biosynthesis 
Co-expression of chaperones 
Substrate availability 
 
Co-expression of uptake systems 
Modulation of efflux systems 
1 
Uncoupling of NAD(P)H oxidation and product formation, see Figure 1.2. 
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1.4 Aim of the work 
 
This work can be thematically divided into two parts. In the first part, it should be studied, if human 
steroidogenic P450s can contribute to the biotransformation of drugs in addition to their biosynthetic 
functions. Therefore, all 6 steroidogenic P450s should be expressed in E. coli and purified to 
homogeneity for substrate conversion assays in an in-vitro system reconstituted with their natural redox 
partners. Steroidal drugs from the groups of anabolic androgenic steroids (AAS) and mineralocorticoid 
receptor antagonists were selected as promising candidates for a transformation, because individual 
compounds from these groups have recently been shown to be metabolized by CYP11B1 and CYP11B2 
(Zöllner et al., 2010b; Parr et al., 2012; Hobler, 2013). The turnover of positive hits from the substrate 
conversion assay should be kinetically characterized in detail with the reconstituted system to evaluate 
the putative physiological relevance of product formation. Structural characterization of the metabolites 
should by performed by nuclear magnetic resonance spectroscopy or mass spectrometry to elucidate the 
new enzymatic properties of the respective steroidogenic P450s. As P450 metabolism is known to 
significantly influence the bioactivity of drugs leading to severe adverse effects, selected metabolites 
will be functionally characterized regarding their effect on the mineralocorticoid receptor, whose 
activation is a crucial step in the regulation of blood pressure and hence the development of 
hypertension.  
In the second part, the establishment of efficient, economic CYP11B1- or CYP21A2-dependent 
biocatalysts should be realized. CYP11B1 and CYP21A2 exhibit selective steroid hydroxylase activities 
for positions 11β and 21, respectively, and their employment for a sustainable production of 
pharmaceutical glucocorticoids is desirable, but currently available systems with recombinant yeast 
suffer from poor efficiencies (Szczebara et al., 2003; Hakki et al., 2008; Zehentgruber et al., 2010). 
Therefore, the respective natural P450 redox system will be reconstituted in E. coli by recombinant 
expression for substrate conversion with intact viable cells. In order to overcome the limitations of poor 
expression in bacteria, limited catalytic activity of the P450 itself and low electron transfer rates, the 
system should be engineered by side directed mutagenesis and molecular evolution of the P450, 
modulation of the expression level of the redox partners and replacement of the autologous redox 
partners by heterologous ones. 
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2. Publications 
 
The results of this work were published in the articles listed below (2.1, 2.2 and 2.3).  
A forth manuscript (2.4) is under review for publication after submission during the release of this 
thesis.  
Additionally, a review article (2.5) was published by the author during the time of the doctoral research.  
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Abstract  
The human mitochondrial cytochromes P450 CYP11A1, CYP11B1 and CYP11B2 are involved in the 
biosynthesis of steroid hormones. CYP11A1 catalyzes the side-chain cleavage of cholesterol and 
CYP11B1 and CYP11B2 catalyze the final steps in the biosynthesis of gluco- and mineralocorticoids, 
respectively. This study reveals their additional capability to metabolize the xenobiotic steroid oral-
turinabol (OT), which is a common doping agent. By contrast, microsomal steroid hydroxylases did not 
convert OT. Spectroscopic binding assays revealed dissociation constants of 17.7 µM and 5.4 µM for 
CYP11B1 and CYP11B2, respectively, while no observable binding spectra emerged for CYP11A1. 
Catalytic efficiencies of OT conversion were determined to be 46 min-1 mM-1 for CYP11A1,  
741 min-1 mM-1 for CYP11B1 and 3338 min-1 mM-1 for CYP11B2, which is in the same order of 
magnitude as for the natural substrates, but shows a preference of CYP11B2 for OT conversion. 
Products of OT metabolism by the CYP11B subfamily members were produced at mg-scale with a 
recombinant Escherichia coli-based whole-cell system. They could be identified by NMR to be 11β-OH-
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OT for both CYP11B isoforms, whereby CYP11B2 additionally formed 11β,18-diOH-OT and 11β-OH-
OT-18-al, which rearranges to its tautomeric form 11β,18-expoxy-18-OH-OT. CYP11A1 produces six 
metabolites, which are proposed to include 2-OH-OT, 16-OH-OT and 2,16-diOH-OT based on LC-
MS/MS analyses. All three enzymes are shown to be inhibited by OT in their natural function. The 
extent of inhibition thereby depends on the affinity of the enzyme for OT and the strongest impact was 
demonstrated for CYP11B2. These findings suggest that steroidogenic cytochromes P450 can contribute 
to drug metabolism and should be considered in drug design and toxicity studies. 
 
Abbreviations: AAS, anabolic androgenic steroids; AdR, adrenodoxin reductase; Adx, adrenodoxin; 
CPR, cytochrome P450 reductase; CYP, cytochrome P450, DOC, 11-deoxycorticosterone; IMAC, 
immobilized metal ion affinity chromatography; OT, oral-turinabol 
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Introduction  
In humans most steps of steroid biosynthesis are 
catalyzed by monooxygenases from the 
cytochrome P450 superfamily (CYP), which 
synthesize glucocorticoids, mineralocorticoids 
and sex hormones. Steroidogenesis is initiated by 
CYP11A1, which cleaves the side-chain of 
cholesterol thereby producing pregnenolone, the 
common precursor for all steroid hormones. 
Additionally, CYP11A1 can convert a variety of 
other sterol derivatives as well as vitamins D2 
and D3 (Slominski et al., 2015), and a set of 
endogenous steroid intermediates (Mosa et al., 
2015). CYP21A2 generates the substrates for 
gluco- and mineralocorticoid biosynthesis by its 
21-hydroxylase activity. CYP11B1 and 
CYP11B2 subsequently synthesize gluco- and 
mineralocorticoids. CYP11B1 catalyzes the 11β-
hydroxylation of 11-deoxycortisol yielding the 
glucocorticoid cortisol. CYP11B2 catalyzes 
hydroxylations of 11-deoxycorticosterone (DOC) 
in positions 11β and 18, followed by an 18-
oxidation to give aldosterone, the major 
mineralocorticoid. CYP17A1 represents the 
branch point to the biosynthesis of sex hormones 
by its 17α-hydroxylase and 17,20-lyase activities. 
CYP19 can, finally, aromatize androgens to 
estrogens (Bernhardt and Waterman, 2007). CYP 
catalysis requires the presence of a suitable 
electron transport system, which delivers the 
electrons necessary for the activation of 
molecular oxygen from the external electron 
donor NADPH. The mitochondrial CYPs, 
CYP11A1 and the two CYP11B isoforms, 
depend on a class I redox system, which consists 
of the FAD containing, NADPH-dependent 
ferredoxin reductase, adrenodoxin reductase 
(AdR), and an [2Fe-2S] ferredoxin, adrenodoxin 
(Adx). The microsomal CYPs CYP17A1, CYP19 
and CYP21A2 are supported by a single electron 
transfer partner (class II redox system), the 
NADPH-dependent cytochrome P450 
oxidoreductase (CPR), which carries FMN and 
FAD centers (Hannemann et al., 2007). Very 
recently, several studies hint at an involvement of 
steroidogenic CYPs in the biotransformation of 
xenobiotic compounds, which is, according to 
traditional classifications of human CYPs, 
believed to be solely conducted by microsomal 
isoforms from the liver (Guengerich, 2001). 
CYP21A2 and both CYP11B isoforms were 
shown to be involved in the metabolism of the 
synthetic anabolic androgenic steroid (AAS) 
metandienone (Zöllner et al., 2010; Parr et al., 
2012) and there are even indications for the 
contribution of CYP11B1 to the bioactivation of 
the non-steroidal environmental pollutant 3-
methylsulfonyl-2,2-bis(4-chlorophenyl)-1,1-
dichloroethene (Lund and Lund, 1995).  
In this study, we aimed to characterize the 
putative metabolism of the AAS oral-turinabol 
(OT) by steroid hormone-synthesizing CYPs to 
further expand our understanding of their 
substrate specificity and possible participation in 
biotransformation. Anabolic agents and, in 
particular, AAS are widely misused for doping 
purposes in all sports. Among them, especially 
17α-alkylated AAS like OT are popular for their 
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oral availability, which is attributed to a 
reduction of the first pass-effect in the liver due 
to the 17α-alkylation (Fragkaki et al., 2009). 
However, AAS also frequently appear in 
adulterated nutritional supplements leading to an 
unintentional intake of them (Geyer et al., 2008). 
In anti-doping controls, they represent the most 
frequently detected class of substances prohibited 
by the World Anti-Doping Agency (WADA, 
2014). Numerous side effects that include 
physical phenomena, such as cardiovascular risks 
(Angell et al., 2012; Deligiannis and Kouid, 
2012) and increased risks of breast and Leydig 
cell cancer (Chimento et al., 2012; Sirianni et al., 
2012) as well as psychiatric disorders (Palmié et 
al., 2013) are attributed to AAS. Although 
several hypothetical models exist to describe the 
mechanisms behind the cardiovascular issues 
(Melchert and Welder, 1995; Deligiannis et al., 
2006), their ability to explain all symptoms is 
still fr agmentary. Increases in blood pressure up 
to hypertension are described to be secondary to 
increases in blood volume, which can result from 
a disruption of mineralocorticoid signaling 
(Rockhold, 1993). Mineralocorticoids, the most 
important of which are DOC and aldosterone in 
humans, regulate water and electrolyte 
homeostasis by controlling renal water and 
sodium retention as well as potassium secretion 
via the mineralocorticoid receptor (MR) 
signaling pathway (Funder, 1997). Ligand-
induced activation of the cytosolic MR leads to 
the release of bound chaperones and nuclear 
localization, followed by DNA binding, the 
recruitment of specific co-activators, which 
subsequently initiates the transcription of specific 
target genes (Galigniana et al., 2004).  
Here, we analyzed the metabolism of the 
xenobiotic steroid OT by human steroidogenic 
CYPs on the molecular level in order to explore 
their drug-metabolizing capabilities. Therefore, 
we took advantage of the recombinant, high-yield 
expression of these enzymes in the bacterial host 
Escherichia coli (E. coli), which only recently 
became feasible for all of these CYPs. 
Dissociation constants were determined by 
UV/Vis-spectroscopy to enable a comparison 
with affinities towards endogenous substrates and 
kinetic studies on OT metabolism were carried 
out using a reconstituted in-vitro system with 
purified enzymes combined with HPLC analysis. 
Metabolites were characterized by tandem mass 
spectrometry or produced with an E. coli whole-
cell system and purified for NMR 
characterization. Additionally, potential 
physiological consequences of OT metabolism 
were investigated by demonstrating the influence 
of OT on the natural CYP function in a 
reconstituted system and by studying the effect of 
the metabolites on MR transactivation in a 
reporter gene assay.  
Materials and Methods 
Chemicals 
All reagents were obtained from standard sources 
with the highest purity available. OT (4-Chlor-
17β-hydroxy-17α-methylandrosta-1,4-dien-3-on) 
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was kindly provided by the Center for preventive 
Doping Research (German Sports University 
Cologne, Germany). Other steroids were 
purchased from Sigma-Aldrich (St. Louis, MO). 
Bacterial media were purchased from Becton 
Dickinson (Heidelberg, Germany), isopropyl β-
D-1-thiogalactopyranoside and 5-aminolevulinic 
acid from Carbolution Chemicals (Saarbruecken, 
Germany).  
Protein expression and purification  
Expression and purification of CYPs 
All CYPs were expressed with a C-terminal poly-
histidine tag from a pET-17b or pET-22b 
(Invitrogen, Life Technologies, Carlsbad, CA) 
vector in E. coli C43(DE) and purified as 
previously described with slight modifications, if 
necessary. The human CYP11A1 cDNA 
sequence (Chung et al., 1986) encoding I301 
instead of M301 was modified as described by 
(Woods et al., 1998) and was expressed and 
purified by IMAC and ion-exchange as presented 
for bovine CYP11A1 (Neunzig and Bernhardt, 
2014) with slight modifications demanded for 
ion-exchange due to differences in pI. After 
IMAC the eluate was dialyzed over night against 
buffer A (20 mM potassium phosphate, pH 6.8, 
20% glycerol, 0.1 mM EDTA, 0.1 mM DTE, 1% 
Na-Cholate, 0.1% Tween 20) and applied to the 
SP sepharose fast flow column (GE Healthcare 
Life Sciences, Freiburg, Germany) equilibrated 
with buffer A. The column was washed with 
buffer A followed by buffer A containing 30 mM 
potassium phosphate, pH 6.8. CYP11A1 was 
subsequently eluted with buffer B (40 mM 
potassium phosphate buffer, pH 7.4, 20% 
glycerol, 0.1 mM EDTA, 0.1 mM DTE, 1% Na-
Cholate, 0.1% Tween 20), which was the 
replaced by buffer C (50 mM potassium 
phosphate buffer, pH 7.4, 20% glycerol, 0.1 mM 
EDTA, 0.1 mM DTE, 1% Na-Cholate, 0.05% 
Tween 20) by dialysis. Human CYP11B1, 
CYP11B2 and CYP21A2 were expressed and 
purified by IMAC and ion exchange as 
previously described by (Zöllner et al., 2008), 
(Hobler et al., 2012) and (Arase et al., 2006), 
respectively. Human CYP17A1, modified as 
described by Imai 1993, was purified by IMAC 
according to (Khatri et al., 2014a; Petrunak et al., 
2014) as well as human CYP19 according to 
(Khatri et al., 2014b). Final CYP concentrations 
were determined by CO-difference spectroscopy 
(Omura and Sato, 1964) with a molar extinction 
coefficient ε=91 mM-1 cm-1. 
Expression and purification of redox partners  
AdR (Sugiyama and Yamano, 1975; Sagara et 
al., 1993) and Adx (Uhlmann et al., 1992; 
Schiffler et al., 2004) were expressed in E. coli 
and purified as previously described. 
Concentrations were determined with ε450 nm=11.3 
mM-1 cm-1 mM for AdR and ε414nm=9.8 mM
-1 cm-
1 for Adx. CPR was expressed in C43(DE) as N-
terminally truncated version with a C-terminal 3-
glycine-6-histidine tag and purified by IMAC as 
described (Sandee and Miller, 2011). The 
truncation of 27 amino acids at the N-terminus 
enables high-yield expression of a soluble, 
2.3 Schiffer et al. 2015, Drug Metab Dispos, DOI 10.1124/dmd.115.066829 
 
57 
 
catalytically active CPR. Slight modifications 
were made during the purification: Triton was 
replaced by 1 % of sodium cholate in all buffers 
and imidazole was used for washing and elution 
at 30 and 200 mM concentrations, respectively. 
For the removal of imidazole the protein was 
finally dialyzed against buffer C described above. 
CPR concentration was determined using 
ε585nm=2.4 mM
-1 cm-1 (Vermilion and Coon, 
1978) for the semi-quinone form. Bovine 
cytochrome b5 was purified as reported 
previously by others (Neunzig et al., 2014). 
In-vitro conversion and enzyme activity assay 
In-vitro substrate conversion was carried out at 
37 °C with a reconstituted system in 50 mM 
HEPES (pH 7.4) supplemented with 20 % 
glycerol and 100 µM 1,2-dilauroyl-sn-glycero-3-
phosphocholine (DLPC). Prior to use, the buffer 
was sonicated in a sonication water bath for 5 
minutes for the reconstitution of DLPC vesicles. 
The system contained 0.5 µM of the CYP, 1 mM 
MgCl2 and 1 mM NADPH as well as a NADPH-
regenerating system composed of 5 mM glucose-
6-phosphate, 4U/ml glucose-6-phosphate 
dehydrogenase. For mitochondrial CYPs 0.5 µM 
AdR and 10 µM Adx were added, in case of 
microsomal CYPs 1 µM of CPR. For CYP17A1 
reactions including 2 µM of bovine cytochrome 
b5 were additionally performed. Substrate was 
added in the respective concentration from a 
stock solution in ethanol or in 2-hydroxypropyl-
β-cyclodextrin with a final concentration of 0.225 
% in case of cholesterol. Final ethanol 
concentration was adjusted within each set of 
reactions. It was kept between 2 and 3 % (2 % for 
the kinetic studies with CYP11B1 and CYP11B2, 
3 % for the kinetic studies with CYP11A1due to 
the higher OT concentrations required for 
saturation, 3 % for CYP11B inhibition 
experiments and 2 % for CYP11A1 inhibition 
experiments, because cholesterol was added from 
a solution in cyclodextrines), whereby no impact 
on reaction kinetics was observed in that range. 
Steroids were extracted twice with chloroform, 
evaporated and suspended in acetonitrile for 
HPLC analysis. For product quantification, 
progesterone was added as an internal standard 
prior to extraction and quantification was 
performed by HPLC using a calibration curve. 
For OT turnover, product formation was 
calculated from the applied OT concentration 
deducting OT consumption, which was 
determined with a calibration curve. In order to 
monitor CYP11A1-dependent conversion of 
cholesterol to pregnenolone at 240 nm, the 
samples were boiled for 5 min in a water bath 
after the respective reaction time and a 
subsequent cholesterol oxidase reaction was 
performed for 1 h at 37 °C, which enables 
detection of the steroids as cholestenone and 
progesterone. Cortisol was used for 
quantification of product formation in this case. 
For the determination of kinetic parameters of 
substrate conversion enzyme concentrations were 
scaled down to 0.25 µM CYP, 0.25 µM AdR and 
4 µM Adx in case of CYP11B1 and to 0.1 µM 
CYP, 0.1 µM AdR and 2 µM Adx in case of 
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CYP11B2. For CYP11A1 the conditions 
described above were maintained. Reactions 
were stopped under steady-state conditions by 
freezing in liquid nitrogen. Reaction times were 
between 2 and 15 minutes for CYP11B1 and 
CYP11B2 and 20 to 25 minutes for CYP11A1. 
High Performance Liquid Chromatography 
(HPLC)-UV/vis detection 
Steroids were separated on a Jasco reversed 
phase HPLC system (Jasco, Gross-Umstadt, 
Germany) using a 4.6 ×125 mm NucleoDur C18 
Isis Reversed Phase column (Macherey-Nagel, 
Dueren, Germany) with an acetonitrile/water 
gradient at 40 °C and a flow rate of 0.8 mL/min. 
Steroid pattern was monitored by an UV/Vis 
detector (UV-2 075 Plus, Jasco, Gross-Umstadt, 
Germany) at 240 nm.  
Spectroscopic binding assay 
The determination of dissociation constants was 
performed by difference spectroscopy using 
tandem cuvettes as described (Schenkmann, 
1970) with a Jasco V-630 Spectrophotometer 
(Jasco, Gross-Umstadt, Germany). 1 µM of 
CYP11B1 or CYP11B2 was diluted in 50 mM 
potassium phosphate buffer (pH 7.4) 
supplemented with 20 % glycerol, 0.5 % sodium 
cholate and 0.05 % Tween20 were titrated with 
increasing concentrations of the steroid from 
stock solutions in DMSO and difference spectra 
were recorded from 350-500 nm. Titrations were 
performed 3 times. For the determination of the 
binding dissociation constant (Kd) the averaged 
∆A (peak-to-trough absorbance difference) was 
plotted against the ligand concentration and plots 
were fitted with Origin 8.6 software by either 
hyperbolic regression (∆A=(Amax[S]/Kd+[S])) or 
tight binding quadratic equation (∆A = 
(Amax/2[E]){(Kd+[E]+[S]) - {(Kd+[E]+[S])2 – 
4[E][S]}½ }, whereby ∆A represents the peak-to-
trough absorbance difference at every ligand 
concentration, Amax the maximum absorbance 
difference at saturation, [E] the enzyme 
concentration (1 µM) and [S] the substrate 
concentration. For the measurement of binding 
spectra of CYP11A1 a 5 µM concentration of the 
enzyme was used and 5 µM Adx were added to 
enhance the spectroscopic signal. 
E. coli based whole-cell product formation and 
product purification 
Large-scale substrate conversion by human 
CYP11B2 was conducted with a recombinant E. 
coli whole-cell system as previously described 
for CYP11B1 (Schiffer et al., 2015b). Briefly, E. 
coli C43(DE3) (F– ompT gal hsdSB (rB- mB-) 
dcm Ion λ) were transformed by electroporation 
with the pET-17b based plasmid Twin_11B2 
encoding human CYP11B2, bovine AdR and 
bovine Adx1-108 and the plasmid pGro12 for the 
co-synthesis of the molecular chaperones 
GroEL/ES (Nishihara et al., 1998). 150 mL TB 
media (24 g yeast extract technical, 12 g peptone, 
4 mL glycerol, 4.62 g KH2PO4, 25 g K2HPO4 and 
distilled water ad. 1L) were supplemented with 
100 µg/mL of ampicillin and 50 µg/mL of 
kanamycin in a 2 L-Erlenmeyer flask and were 
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inoculated from an overnight culture. Cultures 
were incubated at 37 °C and 210 rpm until an 
optical density at 600 nm of 0.5 was reached. 
Protein expression was induced by the addition 
of 1 mM isopropyl β-D-1-thiogalactopyranoside, 
1 mM δ-aminolevulinic acid, 4 mg/mL arabinose 
and 50 µg/mL ampicillin and took place at 27.5 
°C and 200 rpm for 24 h. For subsequent 
substrate conversion cells were harvested by 
centrifugation (3200g, 10 min, 18 °C), washed in 
50 mM potassium phosphate buffer (pH 7.4) and 
suspended in 150 mL buffer supplemented with 1 
mM isopropyl β-D-1-thiogalactopyranoside, 4 
mg/mL arabinose, 1 mM δ-aminolevulinic acid, 
50 µg/mL ampicillin and 2 % glycerol in 2 L-
Erlenmeyer flask. OT was added from a stock 
solution in ethanol to a final concentration of 100 
µM and conversion was performed at 27.5 °C 
and 200 rpm for 24h. Steroids were extracted 
twice with one culture volume of ethyl acetate 
and the organic phase was evaporated to dryness. 
Steroids were suspended in acetonitrile and 
separated on a Jasco reversed phase HPLC 
system (Jasco, Gross-Umstadt, Germany) with a 
NucleoDur 100-5 5 x 250 mm C18 ec column 
(Macherey-Nagel, Dueren, Germany) and an 
acetronitrile/water gradient at a flow rate of 3 
mL/min and 40 °C. Steroids were monitored at 
240 nm and fractions containing the desired 
products were collected, evaporated to dryness 
and analyzed by NMR and LC/MS. 
 
 
LC-Q/TOF setup 
Liquid chromatography-high resolution/high 
accuracy (tandem) mass spectrometry (LC-
MS/MS) measurements were conducted using an 
Agilent (Waldbronn, Germany) 6550 iFunnel Q-
TOF LC-MS/MS instrument equipped with a 
Dual AJS electrospray ion source operated at a 
gas temperature of 290 °C and an ionization 
voltage of 3500 V in positive mode. The mass 
spectrometer was calibrated using the 
manufacturers’ protocol allowing for mass errors 
< 5 ppm for the period of analysis. The mass 
analyzer acquired data from m/z 50 to 600 with 
an acquisition time of 200 ms/spectrum, and 
collision energies of MS/MS experiments were 
adjusted between 15 and 25 eV. Liquid 
chromatography was accomplished by means of 
an Agilent 1290 Infinity LC system equipped 
with an Agilent Eclipse XDB-C18 column (5 
µm, 4.6 x 150 mm) protected by a guard column 
of the same material. The eluents were 0.1% 
formic acid in water (A) and 0.1% formic acid in 
acetonitrile (B) run at a flow rate of 1 mL/min, 
enabling gradient elution of the analytes starting 
at 98% A, decreasing to 0% A within 14 min, 
followed by a 4 min re-equilibration period at 
starting conditions. 
NMR characterization of the major metabolites 
The NMR spectra were recorded in CDCl3 with a 
Bruker DRX 500 or a Bruker Avance 500 NMR 
spectrometer at 298 K. The chemical shifts were 
relative to CHCl3 at δ 7.26 (
1H NMR) and CDCl3 
at δ 77.00 (13C NMR), respectively, using the 
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standard δ notation in parts per million. The 1D 
NMR (1H and 13C NMR, DEPT135) and the 2D 
NMR spectra (gs-HH-COSY, gs-NOESY, gs-
HSQCED, and gs-HMBC) were recorded using 
the BRUKER pulse program library. All 
assignments were based on extensive NMR 
spectral evidence. 
Mineralocorticoid receptor transactivation 
assay 
Steroids were analyzed for their ability to 
activate the human mineralocorticoid receptor 
applying the INDIGO Bioscience Human 
Mineralocorticoid Receptor Reported Assay 
System (INDIGO Biosciences, State college, PA) 
following the manufacturer’s protocol in a dose-
dependent manner with concentrations from 2-
20,000 pM. Aldosterone, which was used as 
positive control, was supplied with the assay.   
Results 
In-vitro metabolism assay of OT by human 
steroidogenic CYPs 
Conversion of OT by the human steroid 
hormone-synthesizing CYPs was assayed with 
recombinant proteins purified from E. coli as 
previously described (for references, see 
Materials and Methods). The natural electron 
transfer chain from NADPH to the CYP was 
reconstituted with human Adx and AdR for 
mitochondrial CYPs and CPR for the microsomal 
ones and the reaction was supported by an 
NADPH regenerating system. Putative product 
formation was analyzed by HPLC and is 
summarized in Table 1. It demonstrated OT 
metabolism by CYP11A1 as well as by the two 
isoforms of the CYP11B subfamily. In contrast, 
the microsomal CYPs, CYP17A1, CYP19 and 
CYP21A2, did not show any conversion of this 
AAS. CYP11B1- and CYP11B2-dependent 
conversion of OT showed distinct, but partially 
overlapping product patterns (Figure 1). 
Metabolites with the same retention times in the 
HPLC measurements are assumed to be the same 
OT derivatives. While CYP11B1 forms one main 
metabolite (1) as well as two side products (2 and 
3) in minor amounts, CYP11B2 produces three 
main products (1, 4 and 5) and 3 intermediate (2) 
or side products (3 and 6). For the CYP11B2-
catalyzed reaction time-dependency of the 
product pattern could be observed. Peak area 
portions of metabolites 1 and 2 are reduced over 
the time while those of 4 and 5 are increasing 
(Figure 1 C and D), which suggests that 4 and 5 
are formed from 1 and 2 in a follow-up reaction. 
CYP11A1 converted OT rather unselectively to 
one main product (metabolite 9) and several side 
products (7, 8 and 10-12; HPLC chromatogram 
not shown). As product formation was weak 
compared with CYP11B1 and CYP11B2 and a 
preparative set up did not seem to be feasible, we 
subsequently followed with an LC-MS/MS 
approach to earn the maximal information about 
the metabolites of the CYP11A1-catalyzed 
conversion of OT.   
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Table 1: Metabolism of OT by human steroidogenic CYPs. 
OT conversion was assayed in a reconstituted in-vitro system with NADPH and the natural redoxsystem 
(mitochondrial: AdR and Adx; microsomal: CPR) and was analyzed by HPLC. Product formation is indicated by 
+, no product forming activity by -. A positive control was performed with a natural substrate. cyt b5= cytochrome 
b5, Prog=progesterone, Andro=androstenedione. 
Cytochrome P450 Redox system OT conversion Control reaction 
CYP11A1 mitochondrial + Cholesterol → Pregenenolone 
CYP11B1 mitochondrial + DOC → Corticosterone 
CYP11B2 mitochondrial + DOC → Corticosterone 
CYP17A1 microsomal 
microsomal 
+ cyt b5 
- Prog → 17-OH-Prog 
17-OH-Prog → Andro 
CYP19A1 microsomal - Andro → Esterone 
CYP21A2 microsomal - Prog → DOC 
 
 
Fig. 1: RP-HPLC chromatograms of the in-vitro 
conversion assays of OT by human CYP11B1 and 
CYP11B2. 100 μM OT were incubated at 37 °C with 
a reconstituted CYP-system consisting of 0.5 μM 
CYP, 10 μM Adx and 0.5 μM AdR, 1 mM NADPH 
and an NADPH regenerating system. A - Incubation 
without NADPH for 30 min as negative control. B - 
CYP11B1-dependent conversion of OT for 30 min. C 
and D - CYP11B2-dependent conversion of OT for 10 
min and 30 min, respectively. 
 
LC-MS/MS analysis of CYP11A1-dependent OT 
metabolism 
The mixture of in-vitro CYP11A1-derived 
metabolites was analyzed by LC-MS/MS using 
full scan and product ion scan experiments. By 
means of the accurate masses of mono- and 
dihydroxylated analogs to OT as well as the 
consideration of diagnostic product ions 
generated from protonated molecules of the 
observed analytes, several different metabolic 
products were identified. In Figure 2, the 
extracted ion chromatograms of mono- and 
dihydroxylated OT are illustrated, suggesting the 
formation of at least six metabolites (metabolites 
7-12). The product ion mass spectrum of 
metabolite 7 is depicted in Figure 3 A, 
presenting several product ions indicative for an 
unmodified steroidal A/B-ring system such as 
m/z 155, 169, and 181 in accordance to literature 
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data (Thevis and Schänzer, 2005; Pozo et al., 
2008), which support assigning  metabolite 7 to 
C- or D-ring hydroxylated OT. Metabolite 8 also 
yielded product ions at m/z 155, 169, and 181 
similar to 7 but at substantially different 
abundances (Figure 3 B). Moreover, intense 
product ions at m/z 205 and 207 complemented 
this spectrum, which were suggested to originate 
also from the steroidal A/B-ring based on the 
observed accurate masses and corresponding 
elemental compositions (C12H10ClO and 
C12H12ClO, respectively). However, in the 
absence of further information, a structural 
assignment of this analyte was not possible. The 
product ion mass spectrum of metabolite 9 
contained a characteristic ion at m/z 171 (Figure 
3 C), representing the counterpart to m/z 155 
after hydroxylation. Hence, the location of the 
hydroxyl function is postulated to be within the 
A/B-ring moiety of the steroid. Noteworthy, both 
metabolites 7 and 8 showed two subsequent 
water eliminations to yield a product ion at m/z 
315.149 while 9 predominantly generated a 
product ion at m/z 315.195 as a result of a HCl 
elimination (Figure 3 C, inset), which further 
corroborated an A/B-ring modification of this 
analyte. 
In addition to the aforementioned 
monohydroxylated metabolites of OT, also 
dihydroxylated species were observed by means 
of the accurate mass of the protonated molecules 
(Figure 2, compounds 10-12). Due to the 
comparably low abundance of these analytes and 
the limited amount of features identifiable by 
means of ESI-MS/MS experiments, further 
studies into the structural compositions were 
conducted only for metabolite 11 (Figure 3 D). 
Here, the same product ion as observed in case of 
product 9 was observed at m/z 171, suggesting 
the location of one hydroxyl function at the A/B-
ring of the metabolite. In addition, the protonated 
molecule at m/z 367 was found to release HCl 
(36 Da) followed by two consecutive water 
losses to yield m/z 331, 313, and 295, 
respectively. Assuming that the significant proton 
affinity of the conjugated π-electron system of 
the A-ring leads to charge-remote elimination 
processes, a location of the second hydroxyl 
function at the steroidal C/D-ring system is 
likely. 
 
Fig. 2: Extracted ion chromatograms of CYP11A1-
derived mono- and dihydroxylated OT. 100 μM OT 
were incubated at 37 °C with a reconstituted CYP-
system consisting of 0.5 μM CY11A1, 10 μM Adx 
and 0.5 μM AdR, 1 mM NADPH and an NADPH 
regenerating system.Protonated molecules of steroids 
[M+H]+ as measured by LC-ESI-MS are shown with 
A - metabolites 7, 8 and 9 representing 
monohydroxylated OT (m/z 351), and B - metabolites 
10, 11 and 12 representing dihydroxylated OT (m/z 
367). 
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 Fig. 3: Product ion mass spectra of protonated 
CYP11A1-derived OT products at m/z 351 and m/z 
367. A - Product 7: Product ion mass spectrum of m/z 
351, collision energy: 15 eV; RT= 7.5 min. B – 
Product 8: Product ion mass spectrum of m/z 351, 
collision energy: 15 eV; RT =8.0 min. C – Product 9: 
Product ion mass spectrum of m/z 351, collision 
energy: 25 eV; RT = 9.3 min. D – Product 11: Product 
ion mass spectrum of m/z 367, collision energy: 25 
eV; RT = 7.7 min. Proposed structures of the 
respective OT metabolites are shown. Fragmentation 
and the resulting fragment ion masses are indicated. 
Determination of dissociation constants and 
kinetic parameters 
In order to assess the efficiency of OT 
metabolism by the human CYP11 family 
members, in-vitro characterization of substrate 
affinity and reaction kinetics was performed. For 
CYP11B1 and CYP11B2 a high-spin shift of the 
heme iron was observed upon OT binding. This 
feature was used to determine dissociation 
constants (Kd) from the type-I difference spectra 
recorded during the titration of the CYP with 
increasing concentrations of OT (Figure 4). 
CYP11B2 showed a Kd value of 5.4 ± 0.4 µM, 
while CYP11B1 has less affinity for OT with a 
Kd of 17.7 ± 2.2 µM. CYP11A1, however, 
showed a putative type-II-like difference 
spectrum with a minimum around 405 nm and a 
maximum between 422 and 424 nm, which was 
not quantifiable even under high CYP 
concentrations and in the presence of Adx 
(Figure 4 C). The observation of a type-II 
difference spectrum with OT arises unexpectedly 
as all other type-II ligands described in the 
literature, to our knowledge, possess a nitrogen 
atom, whose association with the heme iron 
induces a low spin shift. The spin state 
equilibrium can, however, also be influenced by 
distortions of the porphyrin molecule (Groenhof, 
2007). Because of the small size of OT compared 
with cholesterol, two molecules of OT might 
bind in the active site resulting in a very close 
position of one OT molecule above the heme. 
Putative emerging substrate-induced heme 
deformation could then lead to a spin-state 
crossover towards the low-spin state.   
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Fig. 4: Spectroscopic characterization of OT binding by the CYP11 family. A, B - Determination of OT 
affinity to CYP11B1 (A) and CYP11B2 (B) by difference spectroscopy and regression of the absorbance shift. 1 
μM of the respective CYP11B isoform was titrated with increasing concentrations of OT in tandem cuvettes and 
difference spectra were recorded from 350-500 nm (insets). Peak to trough differences of the resulting type-I 
spectra were plotted against the OT concentration and dissociation constants were determined by hyperbolic 
regression for CYP11B1 (R2 0.98) and tight binding quadratic equation for CYP11B2 (R2 0.99). Measurements 
were performed in triplicates. C – Difference spectra of CYP11A1 upon addition of OT and 22(R)-OH-cholesterol. 
5 μM of CYP11A1 were supplemented with its substrates in saturating concentrations in the presence of Adx at 
equimolar concentration. 
 
Fig. 5: Determination of kinetic parameters for OT conversion by human CYP11B1 (A), CYP11B2 (B) and 
CYP11A1 (C) in a reconstituted in-vitro system. The system was reconstituted with the respective CYP, Adx 
and AdR at a ratio of 1:20:1. Reactions took place at 37 °C in presence of an NADPH-regenerating system and 
were stopped under steady-state conditions. OT consumption was determined by HPLC using progesterone or 
cortisol as an internal standard. All values represent the mean of triplicates with standard deviation. Kinetic 
parameters were ascertained by hyperbolic regression (R2 0.96 for CYP11B1 and CYP11B2, R2 0.98). 
Moreover, we determined kinetic parameters of 
OT conversion by performing in-vitro reactions 
under steady-state conditions and quantification 
of OT consumption (Figure 5). Molar ratios of 
the CYP and its redox partners were 1:20:1 
(CYP:Adx:AdR) as the excess of Adx excludes 
the electron transfer to the CYP as limiting step 
and maximum activities of CYP11 systems are 
observed at CYP:AdR ratios ≥1 upon Adx excess 
(Seybert et al., 1978; Seybert et al., 1979; 
Lambeth et al., 1982). For CYP11B2, formation 
of the downstream products was approximately 
20 % under these reaction conditions, so that the 
parameters primarily describe the first 
hydroxylation reaction. The resulting parameters 
KM, kcat and the catalytic efficieny kcat/KM are 
summarized in Table 2.  
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Table 2: Kinetic parameters of OT conversion by 
CYP11B1, CYP11B2 and CYP11A1 determined as 
shown in Figure 5. 
 KM 
[µM] 
kcat 
[min
-1
] 
kcat/KM 
[min-1mM-1] 
CYP11B1 33 ± 9 25 ± 2 741 
CYP11B2 10 ± 2 34 ± 2 3338 
CYP11A1 136 ± 21 6 ± 0.4 46 
  
Influence of OT on natural substrate 
conversion 
The binding and metabolism of OT at relevant 
catalytic rates by the three enzymes suggests 
possible interference with the conversion of their 
natural substrates. In-vitro conversions using 
cholesterol as substrate for CYP11A1 and DOC 
for CYP11B1 and CYP11B2 in the presence of 
increasing OT concentrations demonstrate the 
capability of OT to inhibit steroid biosynthesis on 
enzymatic level (Figure 6). Product formation 
was inhibited for all three enzymes in a 
concentration-dependent manner with a stronger 
effect on CYP11B2 than on CYP11B1 and 
CYP11A1, which are influenced to a comparable 
extent. With a five-fold excess of OT over the 
respective natural substrate, CYP11A1- and 
CYP11B1-dependent product formation was 
reduced to 42 and 49 %, respectively, while 
CYP11B2-dependent product formation was 
reduced as low as 12 %. The regulation of steroid 
biosynthesis is also the result of signaling on 
multiple levels (hypothalamic-pituitary-adrenal 
axis, renin-angiotensin system etc.). A deeper 
characterization of the inhibitory effects of OT 
was thus not considered as conducive for the 
interpretation of their relevance. 
Fig. 6: Relative product formation from the 
natural substrates in the presence of OT in a 
reconstituted in-vitro system. The system consisted 
of 0.5 μM CYP, 10 μM Adx and 0.5 μM AdR, 1 mM 
NADPH and an NADPH regenerating system and the 
reaction took place at 37 °C for 1 min for the CYP11B 
isoforms and 10 min for CYP11A1. DOC was used as 
a substrate for CYP11B1 and CYP11B2, cholesterol 
for CYP11A1. The substrate concentration was 20 μM 
to ensure conditions below the saturation but in an 
excess over the CYP and OT was added in the 
indicated ratios. DOC consumption or pregnenolone 
formation was determined by HPLC using 
progesterone or cortisol, respectively, as an internal 
standard. Each bar represents the mean of three 
reactions with respective standard deviation. 
E. coli based whole-cell OT conversion 
Preparative scale production of the OT 
metabolites formed by the  CYP11B isoforms for 
NMR characterization and further investigation 
of the major metabolites was performed with an 
E. coli-based whole-cell conversion system as 
previously reported for CYP11B1-dependent 
transformation of 11-deoxycortisol to cortisol 
(Schiffer et al., 2015b). As CYP11B1 products 
are also formed by CYP11B2, application of 
CYP11B2 was chosen. The complete redox chain 
was transferred into E. coli by co-expression of 
CYP11B2, bovine AdR and truncated bovine 
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Adx1-108 from a tricistronic plasmid. Functional 
folding was supported by the overexpression of 
the molecular chaperones GroEL/ES (Nishihara 
et al., 1998). The CYP11B2 whole-cell 
biocatalyst was applied for the conversion of 100 
µM OT under non-growing conditions to 
maximize the availability of NADPH for the 
CYP11B2 reaction. After 24 h approximately 90 
% of OT was converted with the same product 
pattern as observed in-vitro (data not shown). 
Individual yields for the three major products as 
estimated by peak area portions were about 30, 
33 and 23 % for metabolites 1, 4 and 5, 
respectively. All three products were purified in 
mg amounts by preparative HPLC.  
NMR characterization of the OT metabolites 
Purified products were structurally characterized 
by NMR spectroscopy. Elucidated structures are 
illustrated in Figure 7. 
Metabolite 1 - 11β-OH-OT (4-Chlor-11β,17β-
dihydroxy-17α-methylandrosta-1,4-dien-3-one). 
In comparison to oral-turinabol the 1H and 13C 
NMR spectra of its conversion metabolite 1 
showed signals for an additional secondary 
hydroxyl group (δH 4.44 td; δc 70.36) which 
could be located at C-11 by means of 2D NMR. 
For example its proton showed correlations to H-
9 (δ1.07, dd) and H-12a (δ1.57, dd) and H-12b 
(δ1.64, dd) in the HHCOSY. H-11 must be in 
equatorial position due to its small coupling 
constants to H-9 (J=3.7 Hz) and to both H-
12(J=2.5 and 3.7 Hz) and is therefore in α-
orientation. In consequence of this fact the 
hydroxyl at C-11 is β-orientated. 1H NMR 
(CDCl3,500 MHz): δ 1.07 (dd, 11.0 and 3.7 Hz, 
H-9), 1.08 (m, H-7a), 1.13 (m, H-14), 1.15 (s, 
3xH-20), 1.18 (s, 3x H-18), 1.44 (qd, 12.0 and 
6.5 Hz, H-15a), 1.53 (s, 3xH-19), 1.57 (dd, 14.2 
and 3.7 Hz, H-12a), 1.64 (dd, 14.2 and 2.5 Hz, H-
12b), 1.65 (m, H-15b), 1.76 (ddd, 14.0, 9.5 and 
6.5 Hz, H-16a), 1.85 (ddd, 14.0, 12.0 and 3.5 Hz, 
H-16b), 2.11 (m, H-7b), 2.14 (m, H-8), 2.39 (td, 
13.8 and 5.3 Hz, H-6a), 3.24 (ddd, 13.8, 4.8 and 
2.3 Hz, H-6b), 4.44 (td, 3.7 and 2.5 Hz, H-11), 
6.39 (d, 10.0 Hz, H-2), 7.32 (d, 10.0 Hz, H-1). 
13C NMR (CDCl3, 125 MHz): δ 16.42 (CH3, C-
18), 21.42 (CH3, C-19), 23.43 (CH2, C-15), 
25.87 (CH3, C-20), 28.23 (CH2, C-6), 32.05 
(CH, C-8), 32.40 (CH2, C-7), 38.67 (CH2, C-16), 
41.00 (CH2, C-12), 44.78 (C, C-13), 46.79 (C, C-
10), 50.94 (CH, C-14), 56.22 (CH, C-9), 70.36 
(CH, C-11),  81.76 (C, C-17), 126.62 (CH, C-2), 
127.23 (CH, C-4), 155.84 (CH, C-1), 163.37 (C, 
C-5), 178.57 (C, C-3). 
Metabolite 4 - 11β,18-Di-OH-OT (4-Chlor-
11β,17β,18-trihydroxy-17α-methylandrosta-1,4-
dien-3-one). The NMR spectra of metabolite 4 
were similar to those of 1, especially for the 
resonances of C-11 (δC 69.12) and H-11 (δH 
4.39 q, 3.3 Hz) as well as the coupling pattern of 
H-11, but P2 lacked of resonances for methyl C-
18. Therefore, signals for a primary hydroxyl 
group at δH 4.00 (d, 11.3 Hz), 4.04 (d, 11.3 Hz) 
and δC 63.49 appeared in the spectra. Data thus 
obtained led to the 11β, 18 dihydroxy derivative 
of oral-turinabol. 2D NMR measurements 
supported the structure and led to the full  
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Fig. 7: Hydroxylation and oxidation of OT catalyzed by the human CYP11B subfamily. Structures were 
revealed by NMR spectroscopy after CYP-dependent whole-cell catalysis in E. coli. 
 
assignments. 1H NMR (CDCl3, 500 MHz): δ 1.03 
(dd, 11.3 and 3.3 Hz, H-9), 1.05 (m, H-7a), 1.20 
(s, 3xH-20), 1.21 (m, H-14), 1.29 (m, H-12a), 
1.44 (m, H-15a), 1.54 (s, 3xH-19), 1.69 (m, H-
15b), 1.82 (ddd, 14.0, 9.5 and 7.0 Hz, H-16a), 
2.08 (m, H-16b), 2.09 (m, H-7b), 2.20 (m, H-8), 
2.33 (m, H-12b), 2.39 (td, 14.0 and 5.4 Hz, H-
6a), 3.25 (ddd, 14.0, 4.8 and 2.7 Hz, H-6b), 4.00 
(d, 11.3 Hz, H-18a), 4.04 (d, 11.3 Hz, H-18b), 
4.39 (q, 3.3 Hz, H-11), 6.39 (d, 10.0 Hz, H-2), 
7.38 (d, 10.0 Hz, H-1). 13C NMR (CDCl3, 125 
MHz): δ 21.16 (CH3, C-19), 23.97 (CH2, C-15), 
27.04 (CH3, C-20), 28.21 (CH2, C-6), 32.07 
(CH, C-8), 32.70 (CH2, C-7), 34.19 (CH2, C-12), 
39.21 (CH2, C-16), 46.90 (C, C-10), 48.31(C, C-
13), 50.38 (CH, C-14), 56.50 (CH, C-9), 63.49 
(CH2, C-18), 69.12 (CH, C-11),  83.49 (C, C-17), 
126.44 (CH, C-2), 127.24 (CH, C-4), 156.10 
(CH, C-1), 163.08 (C, C-5), 178.57 (C, C-3). 
Metabolite 5 - 11β,18-Epoxy-18-OH-OT (4-
Chlor-11β,18-epoxy-17β,18-dihydroxy-17α-
methylandrosta-1,4-dien-3-one). The NMR 
spectra of metabolite 5 revealed a (11-18)-hemi-
acetal function. This was obvious by the 
characterictic acetal resonance for C-18 (δC 
99.40, CH) and its correlation with the hydroxyl 
proton H-11 (δH 4.77 d) in the HMBC. Thus, the 
structure of metabolite 5 represented the 
tautomeric form of the 11β-hydroxy-18-aldehyde 
derivate of oral-turinabol. 1H NMR (CDCl3, 500 
MHz): δ 1.04 (d, 10.7 Hz, H-9), 1.10 (m, H-7a), 
1.28 (s, 3xH-20), 1.49 (m, H-14), 1.28 (d, 11.5 
Hz, H-12a), 1.53 (m, H-15a), 1.36 (s, 3xH-19), 
1.85 (m, H-15b), 1.95 (m, H-16a and H-16b),  
2.07 (m, H-7b), 1.85 (m, H-8), 2.30 (td, 13.7 and 
4.8 Hz, H-6a), 2.42 (dd, 11.5 and 6.5 Hz, H-12b), 
3.34 (dt, 13.7 and 3.5 Hz, H-6b), 5.32 (s, H-18), 
4.77 (d, 6.5 Hz, H-11), 6.40 (d, 10.0 Hz, H-2), 
7.14 (d, 10.0 Hz, H-1). 13C NMR (CDCl3, 125 
MHz): δ 20.40 (CH3, C-19), 23.34 (CH2, C-15), 
27.40 (CH3, C-20), 28.83 (CH2, C-6), 31.07 
(CH2, C-7), 35.27 (CH2, C-12), 36.92 (CH, C-8), 
39.51 (CH2, C-16), 45.64 (C, C-10), 48.01 (CH, 
C-14), 55.32 (CH, C-9), 57.19 (C, C-13), 75.65 
(CH, C-11),  78.64 (C, C-17), 99.40 (CH, C-18), 
126.63 (CH, C-2), 128.94 (CH, C-4), 154.46 
(CH, C-1), 161.42 (C, C-5), 178.13 (C, C-3).  
Mineralocorticoid receptor activation assay with 
the CYP11B-derived OT metabolites  CYP11B-
derived OT metabolites carry the same oxy-
functionalizations as are introduced into the 
steran scaffold during the biosynthesis of natural 
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mineralocorticoids. Therefore, we evaluated their 
potential to activate the human mineralocorticoid 
receptor in order to investigate putative new or 
altered functions of the OT metabolites. The 
assay was performed with a commercially 
available cell-culture based system, which gives 
a luminescence signal upon activation of the MR. 
Purity of the test compounds was verified by LC-
MS prior to the assay. Test concentrations ranged 
from 2-20,000 pM, which resulted in full dose-
response for the natural MR ligand aldosterone. 
The respective EC50 value of 42 pM is consistent 
with the range of the value given in the 
manufacturer’s protocol. A detectable MR 
activation by OT and its metabolites was 
observed only with the highest assay 
concentration and represented only 30 % of the 
maximum aldosterone response (Figure 8). The 
modifications at C11 and C18 introduced by 
CYP11B2 did not alter the agonist potential of 
OT.  
Discussion 
Human CYPs are traditionally classified into a 
group of drug-metabolizing CYPs expressed in 
the liver and those that carry out the biosynthesis 
of endogenous compounds such as steroid 
hormones. In this study, we examined whether 
the second group might additionally contribute to 
the metabolism of xenobiotics by investigating 
the synthetic steroidal drug OT, which is a 
common doping agent. All six steroidogenic 
CYPs were tested for their activity towards OT. 
While no conversion of OT was found using  
 
Fig. 8: Dose-response analysis of human MR 
activation by OT and its CYP11B-derived 
metabolites. Dilutions of each compound were 
analyzed with INDIGO Bioscience Human 
Mineralocorticoid Receptor Reported Assay System 
following the manufacturer’s protocol. The 
luminescence signal of MR-responsive luciferase 
reporter gene expression was normalized to the signal 
of the vehicle control and is plotted against the test 
compound concentration in logarithmic scale. The 
assay was performed in triplicates for each 
concentration. The black line indicates the Hill-
regression of the aldosterone induced response 
(R2=0.998), the dashed line shows the vehicle 
background signal. 
 
CYP17A1, CYP19 and CYP21A2, the three 
mitochondrial CYPs, CYP11A1 and both 
isoforms of the CYP11B subfamily, efficiently 
catalyze conversion of OT with an affinity and 
catalytic efficiency in the same order of 
magnitude as for their natural substrates. 
CYP11B2 binds OT with a Kd only 
approximately four-fold higher than that for the 
natural substrate DOC reported to be 1.34 µM 
(Hobler et al., 2012) and the catalytic efficiency 
(kcat/KM) of OT conversion by CYP11B1 and 
CYP11B2 is even slightly higher than previously 
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determined for the natural substrates (Zöllner et 
al., 2008; Hobler et al., 2012). It is striking that 
CYP11B2 shows a higher activity and affinity for 
OT than CYP11B1. It was postulated that the 
extended functional spectrum of CYP11B2 is 
enabled by an increase in retention time of the 
intermediates in the active site due to higher 
intrinsic flexibility compared with CYP11B1 
(Strushkevich et al., 2013). A reduced flexibility 
of CYP11B1 might impede the access of the non-
natural substrate to the active site and thus 
matches the lower binding affinity and catalytic 
efficiency of CYP11B1 towards OT.  
As revealed by NMR characterization of the 
products, both CYP11B isoforms catalyze the 
same reactions with OT as with their natural 
substrates. An 11β-hydroxylation is performed by 
both enzymes and an additional subsequent 18-
hydroxylation and 18-oxidation by CYP11B2. To 
the best of our knowledge, the respective 
products have not been described in the literature 
so far. We can hypothesize the structure of 
metabolites based on studies on natural substrates 
(Kawamoto et al., 1990; Bureik et al., 2002a; 
Hobler et al., 2012). CYP11B1 and CYP11B2 
generate the intermediate product 2 that is 
hypothesized to be 18-OH-OT. Metabolite 3 can 
be assumed to be a 19-hydroxylated OT 
derivative (Schiffer et al., 2015a). OT is thus the 
first exogenous substrate, which is described to 
undergo all three reactions catalyzed by 
CYP11B2 with the same regio- and 
stereoselectivity as the endogenous substrate. The 
CYP11B2 crystal structure in complex with DOC 
(Strushkevich et al., 2013) revealed that it is 
bound to the active site via its 3-keto and 21-
hydroxy groups. The absence of the second group 
in OT does conclusively not negatively influence 
the selectivity or advancement of the catalytic 
reaction. However, the 3keto-∆4 motif, which 
was already supposed to be conserved among all 
CYP11B substrates using endogenous steroids 
(Strushkevich et al.), is preserved and seems to 
be sufficient for proper binding. Interestingly, 
CYP11B2 metabolism of metandienone, which is 
structurally identical to OT except for the 4-
chloro group, comprises only 
monohydroxylations in position 11β and 18 (Parr 
et al., 2012). When compared with the 
metabolites formed from OT by CYP11B2, the 
differences between OT and metandienone 
metabolism lead to the suggestion that the C4 
substitution of OT determines the processivity of 
the reaction.  
It is worth mentioning that the conducted 
bioconversion of OT by CYP11B2 at preparative 
scale represents the first application of human 
CYP11B2 for substrate conversion in E. coli, 
which has so far only been used for 
biotechnological purposes in recombinant yeast 
strains (Bureik et al., 2002b). Despite working 
under non-optimized shake flask conditions, the 
volumetric productivity of OT consumption of 
approximately 30 mg*L-1*d-1 reaches the 
minimum requirements for potential application 
in industrial pharmaceutical production (Julsing 
et al., 2008). CYP11B2-dependent aldosterone 
biosynthesis plays a crucial role in the regulation 
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of blood pressure and related diseases (Ardhanari 
et al., 2015), whose medicinal treatment by 
selective CYP11B2 inhibitors currently regains 
interest (Andersen, 2013; Hargovan and Ferro, 
2014; Namsolleck and Unger, 2014). The 
presented system might alternatively serve as 
simple, economic pre-screening for the 
effectiveness of potential inhibitors upon down-
scaling to a multi-well format.  
Compared with the two CYP11B enzymes, 
CYP11A1 exhibits a lower efficiency of OT 
conversion (46 min-1 mM-1 compared with 741 
and 3338), which is also lower than for the 
natural substrate cholesterol. Bovine CYP11A1 
shows an efficiency of approximately 85 min-1 
mM-1 for cholesterol (Neunzig and Bernhardt, 
2014; Mosa et al., 2015). The low catalytic 
efficiency for OT is, however, consistent with the 
observed activities towards endogenous steroids 
(Mosa et al., 2015) and the preference of 
CYP11A1 for longer side-chains (Masuo et al., 
1980). Due to low productivity, structural 
assignments for the emerging OT metabolites 
were proposed for three of the six metabolites 
from MS/MS product ion mass spectra and 
previous studies that describe a 2β-, 6β- and 16β-
hydroxylase activity of CYP11A1 for steroids 
(Mosa et al., 2015) (Figure 3). Metabolite 7 
shows an unmodified A/B-ring and an OH-group 
that can be assigned to the C- or D-ring. It is thus 
proposed to be 16-OH-OT. The product ion mass 
spectrum of metabolite 9 provides strong 
indications for an A-ring hydroxylation and as 
positions 3 and 4 are occupied, we suggest 2-OH-
OT as putative structure. Metabolite 11 seems to 
carry a combination of these two hydroxylations 
and is assumed to be 2,16-diOH-OT. 6- and 16-
hydroxylated OT species are already known from 
previous metabolism and excretion studies. In 
humans OT is mainly transformed by reduction 
of the A-ring double bonds and keto group, by 
hydroxylation in positions 6β, 12 and 16β by 
CYP3A4 among others and by rearrangement to 
18-nor-17β-hydroxymethyl derivatives 
(Schänzer, 1996; Schänzer et al., 1996; Rendic et 
al., 1999; Sobolevsky and Rodchenkov, 2012). 2-
OH-OT would hence be another new OT 
metabolite discovered in this study. 
Following the studies about the 
biotransformation of OT by the human 
mitochondrial CYPs, we were also interested to 
examine the effect of OT on the activity of these 
CYPs towards their endogenous substrates. An 
inhibition of the natural function of the OT 
metabolizing CYPs seemed likely, as both, OT 
and the natural substrate, compete for binding to 
the active site with comparable affinities. In fact, 
an inhibitory effect of OT on the conversion of 
natural substrates was demonstrated by our in-
vitro data. Inhibition thereby depends on the 
concentration and mirrors the affinity of the 
CYPs for OT resulting in the highest inhibitory 
effect on CYP11B2. Potential physiological 
relevance is, however, the result of 
concentrations in the microenvironment of 
steroid-synthesizing enzymes and can hardly be 
assessed at this time. Cholesterol level in the 
inner mitochrondrial membrane is controlled by 
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StAR protein activity, which varies upon 
signaling via the hypothalamic-pituitary-adrenal 
axis and other steroidogenic stimuli. Plasma 
levels of the prohormone 19-norandrostenediol 
and its active metabolite nandrolone were 
reported to be in the range of several hundreds of 
nanogramms per 100 mL after a single dose of 
25-100 mg (Schrader et al., 2006), which is in 
excess over DOC and 11-deoxycortisol plasma 
levels (Mason and Fraser, 1975). Exact 19-
norandrostenediol and metabolite plasma levels 
were, however, also dependent on the route of 
administration. DOC levels are generally lower 
than 11-deoxycortisol levels and CYP11B2 is 
expressed at low levels compared with other 
steroidogenic CYPs. These facts and the 
observation of the strongest inhibitory effect of 
OT on CYP11B2, indicate that the biggest effect 
in-vivo of OT can be expected for aldosterone 
synthesis from DOC. This hypothesis of a 
relevant inhibition of CYP11B2-dependent 
aldosterone synthesis by OT coincides with 
AAS-induced increases in DOC levels in rat, 
whose MR-agonist properties induce increases of 
blood pressure (Colby et al., 1970). However, 
this phenomenon has so far only been explained 
on transcriptional level (Brownie et al., 1970; 
Colby et al., 1970; Brownie et al., 1988; Gallant 
et al., 1991). Our new insights suggest additional 
direct effects on an enzymatic level.  
The identification of metabolites and 
characterization of their bioactivity is a crucial 
step in drug design. The elucidation of the MR 
crystal structure with various ligands (Bledsoe et 
al., 2005; Li et al., 2005) displayed that a 
hydrogen bond network between the steroid 
ligand C11 and C18 positions and the ligand 
binding domain is crucial for its activation. The 
alteration of the hydrogen bond forming 
properties of these positions can thus modulate 
the agonist activity of a steroid. We, therefore, 
tested OT and the new metabolites, which are 
produced by the CYP11B enzymes, for their 
potential to activate the MR. It turned out that OT 
acts only as a very weak MR agonist. The new 
metabolites do also not show a relevant 
activation of the MR, although they carry oxy-
functionalization at C11 and C18. An endocrine-
disrupting potential of OT and its metabolites at 
the MR is thus unlikely. It can be hypothesized 
that OT and its metabolites do not induce all 
conformational changes required for activation, 
as they lack the C20-carbonyl and C21-hydroxyl 
functions, which interact with the receptor in case 
of the native ligands (Bledsoe et al., 2005). 
Additionally, it is assumed that the length of the 
ligand also determines the events leading to 
activation (Bledsoe et al., 2005). This assumption 
is consistent with the weak binding of the C19-
steroid 1-testosterone to the MR (Friedel et al., 
2006a) and the higher affinity of 
tetrahydrogestrinone, which has a C17-ethyl 
group (Friedel et al., 2006b).  
Summarizing the results, it was clearly 
demonstrated that OT is, in addition to 
metandienone (Parr et al., 2012), the second 
xenobiotic steroid whose metabolism by 
steroidogenic CYPs has been observed. Our 
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detailed in-vitro studies hint at a potentially 
systematic contribution of human steroidogenic 
CYPs to the metabolism of xenobiotics, which 
suggests their consideration as drug-metabolizing 
enzymes during drug design and toxicity 
evaluation. Their metabolic potential and a need 
for their involvement in drug testing appears 
especially important in case of steroidal drugs, 
which are widely applied to treat a variety of 
anti-inflammatory and contraceptive issues as 
well as for disease- or cancer-conditioned (post-
operative) steroid replacement purposes. Product 
properties might differ from those of the parental 
compound and the interference with the 
endogenous steroid biosynthesis can cause severe 
adverse effects.  
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Abstract 
Spironolactone and its major metabolite canrenone are potent mineralocorticoid receptor antagonists and 
are, therefore, applied as drugs for the treatment of primary aldosteronism and essential hypertension. 
We report that both compounds can be converted by the purified adrenocortical cytochromes P450 
CYP11B1 and CYP11B2, while no conversion of the selective mineralocorticoid receptor antagonist 
eplerenone was observed. As their natural function, CYP11B1 and CYP11B2 carry out the final steps in 
the biosynthesis of gluco- and mineralocorticoids. Dissociation constants for the new exogenous 
substrates were determined by a spectroscopic binding assay and demonstrated to be comparable to 
those of the natural substrates, 11-deoxycortisol and 11-deoxycorticosterone. Metabolites were produced 
at preparative scale with a CYP11B2-dependent E. coli whole-cell system and purified by HPLC. Using 
NMR spectroscopy, the metabolites of spironolactone were identified as 11β-OH-spironolactone, 18-
OH-spironolactone and 19-OH-spironolactone. Canrenone was converted to 11β-OH-canrenone, 18-
OH-canrenone as well as to the CYP11B2-specific product 11β,18-diOH-canrenone. Therefore a 
contribution of CYP11B1 and CYP11B2 to human pharmacokinetics should be taken into account and 
the metabolites should be tested for their potential toxic and pharmacological effects. A 
mineralocorticoid receptor transactivation assay in antagonist mode revealed 11β-OH-spironolactone as 
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pharmaceutically active metabolite, whereas all other hydroxylation products negate the antagonist 
properties of spironolactone and canrenone. Thus, human CYP11B1 and CYP11B2 turned out to 
metabolize steroid-based drugs additionally to the liver-dependent biotransformation of drugs. 
Compared with the action of the parental drug, changed properties of the metabolites at the target site 
have been observed. 
 
Keywords: Aldosterone, hypertension, mineralocorticoid receptor antagonists, human 
CYP11B1/CYP11B2, xenobiotic metabolism 
Abbreviations: AdR – adrenodoxin reductase, Adx – adrenodoxin, DOC – 11-deoxycorticosterone, E. 
coli – Escherichia coli, MR – mineralocorticoid receptor, MRA – mineralocorticoid receptor antagonist, 
RSS – 11-deoxycortisol (Reichstein’s substance S) 
  
Introduction 
Aldosterone represents the main human mineralocorticoid. It regulates renal water and sodium retention 
as well as potassium secretion via the mineralocorticoid receptor (MR) and thereby controls water and 
electrolyte homeostasis, which directly projects onto blood pressure [1-4]. The MR is a ligand-activated 
transcription factor inducing genomic effects upon mineralocorticoid binding, subsequent translocation 
into the nucleus and regulation of transcription [2, 5]. In humans, aldosterone is synthesized from 11-
deoxycorticosterone (DOC) in the zona glomerulosa of the adrenal cortex by a member of the 
cytochrome P450 superfamily (P450), CYP11B2, that catalyzes a reaction sequence consisting of 11β- 
and 18-hydroxylations followed by an 18-oxidation [6-10]. The other member of the human CYP11B 
subfamily, CYP11B1, which shares 93 % sequence identity with CYP11B2 on protein level, synthesizes 
the major human glucocorticoid cortisol in the adrenal zona fasciculata by 11β-hydroxylation of 11-
deoxycortisol (RSS) [6-8, 11, 12]. Both CYP11B isoforms are located in the inner mitochondrial 
membrane and require NADPH as electron donor for their catalysis as well as an electron transfer 
system consisting of the NADPH-dependent adrenodoxin reductase (AdR) and adrenodoxin (Adx), 
which transfers electrons to the P450 for the activation of molecular oxygen [13]. 
Aldosterone induced activation of the MR is a key step in the development of hypertension and resultant 
cardiac and renal abnormalties [14]. In addition, MR activation in cardiac tissues also seems to play a 
direct role in cardiac fibrosis [3]. Consecutively, the MR represents an attractive drug target for blood 
pressure reducing therapies and mineralocorticoid receptor antagonists (MRAs) have been used 
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successfully for decades in the treatment of primary aldosteronism and essential hypertension as well as 
congestive heart failure [15-20]. Spironolactone, which has been clinically applied since the early 1960s, 
is still a widely used MRA and has been shown to reduce the risks of morbidity and mortality among 
patients with severe heart failure [17]. Upon administration, it is rapidly dethioacetylated to its principal 
pharmacologically active metabolite canrenone [21-23]. However, the use of spironolactone is limited 
by its non-selective receptor binding properties, which result in significant adverse effects, most of them 
being sex-related due to binding to the androgen receptor [24, 25]. As a consequence, the development 
of more selective MRAs, such as eplerenone, is of great interest to reduce steroid receptor cross-
reactivity [18, 19, 26].  
During the 1970s, several studies observed an interference of the MRAs spironolactone and canrenone 
with corticosteroid biosynthesis in rat adrenal tissue and mitochondrial preparations from bovine and 
human [27-29]. Furthermore, binding of both compounds to P450s leading to a type-I difference 
spectrum and the formation of hydroxylated MRA metabolites was described [28, 29]. As these studies 
were performed with tissue-derived preparations and the availability of high and pure quantities of each 
of the corticosteroid synthesizing P450s was not given at that time, neither the metabolites nor the 
particular P450s responsible for their formation could be identified. Metabolite identification and 
characterization is, however, crucial for drug design and development due to potential toxicity and 
pharmacological diversification. The recombinant expression of the 2 human mitochondrial 
steroidogenic P450s CYP11B1 and CYP11B2 in E. coli was finally achieved during the last years, 
which now enables an efficient purification and application for biotransformations in preparative scale 
[9, 11, 30]. According to the traditional P450 classification, these isozymes are counted as nondrug-
metabolizing P450s and are presumed to display a narrow substrate spectrum, which is restricted to their 
natural function in steroid hormone biosynthesis [31, 32]. Nevertheless, very recently a few exogenous 
substrates were described for the CYP11B subfamily [33, 34] demonstrating their ability for the 
biotransformation of exogenous compounds. This study presents a new metabolic pathway for 
spironolactone and canrenone catalyzed by CYP11B1 and CYP11B2. Metabolism is demonstrated in a 
reconstituted in-vitro system and emerging metabolites were produced at preparative scale by E. coli 
based whole-cell bioconversions for structural elucidation by NMR. Alterations of their bioactivity 
concerning their antagonist properties for the MR were studied in a transactivation assay.  
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Material & Methods 
Chemicals  
All reagents were purchased from standard sources with the highest purity available. Steroids were 
purchased from Sigma-Aldrich.  
Expression and purification of human CYP11B1 and CYP11B2 
Human CYP11B1 and CYP11B2 were expressed in E. coli C43(DE3) using constructs described [9, 
11]. The expression was performed in 2.8 L Fernbach flasks containing 400 mL TB medium (24 g 
technical yeast extract, 12 g peptone, 4 mL glycerol, 4.6 g KH2PO4, 25 g K2HPO4) supplemented with 
100 µg/ml ampicillin and 50 µg/ml kanamycin. The expression culture was inoculated with an overnight 
culture and incubated at 37 °C and 210 rpm until an OD600 nm of 0.5 was reached. Protein expression was 
induced with 1 mM isopropyl β-D-1-thiogalactopyranoside, 4 mg/mL arabinose, 1 mM δ-aminolevulinic 
acid and 50 µg/ml ampicillin. Further incubation was carried out at 27.5 °C and 180 rpm for 24 h. Cells 
were harvested by centrifugation and sonicated in lysis buffer (50 mM potassium phosphate (pH 7.4),  
20 % glycerol, 500 mM sodium acetate, 1.5 %  sodium cholate, 1.5 % Tween 20, 0.1 mM 
phenylmethylsulfonylflourid, 0.1 mM dithiothreitol). Cell debris was removed by ultracentrifugation (30 
min, 35.000 rpm, 4 °C) and the P450 was purified from the supernatant by immobilized metal ion 
affinity chromatography and cation exchange according protocols established previously [9, 11]. 
Concentrations of the purified cytochromes P450 were determined by reduced carbon-monoxide 
difference spectroscopy with an extinction coefficient ε450nm=91 mM
-1 cm-1 [35]. 
Purification of redox partners 
Human AdR [36, 37] and Adx [38, 39] were expressed in E. coli and purified as previously described. 
Concentrations were determined with ε450 nm=11.3 mM
-1 cm-1 mM for AdR and ε414 nm=9.8 mM
-1 cm-1 for 
Adx. 
In-vitro substrate conversion 
For in-vitro substrate conversion assays, 400 µM of the respective MRA was incubated with the P450 
system that was reconstituted with the natural human redox partners, AdR and Adx. The reaction 
mixture (0.5 mL) consisted of 0.5 µM CYP11B1 or CYP11B2, 0.5 µM AdR and 10 µM Adx in 50 mM 
HEPES buffer pH 7.4 supplemented with 20 % glycerol and 100 µM 1,2-Didodecanoyl-sn-glycero-3-
phosphocholine. Furthermore, a NADPH-regeneration system consisting of 5 mM glucose-6-phosphate, 
4 U/mL glucose-6-phosphate dehydrogenase and 1 mM MgCl2 was added. The reaction was started by 
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adding 1 mM NADPH, incubated at 37 °C under shaking and stopped after 1 h by adding two reaction 
volumes of chloroform. For the conversion assays with natural substrates (RSS for CYP11B1 and DOC 
for CYP11B2) in the presence or absence of the MRAs, enzyme concentrations were down-scaled to 
0.25 µM CYP11B1 or CYP11B2, 0.25 µM AdR and 5 µM Adx. Substrate and the respective MRA were 
added from stock solutions in ethanol with final concentrations of 20 µM substrate and 40 µM MRA and 
a final solvent concentration of 0.6 %. The reaction volume was increased to 750 µL to enable an 
appropriate detection of the steroids in the HPLC measurements. Reactions took place at 37 °C under 
shaking for two min. Progesterone was added as internal standard for quantification. 
Reversed phase HPLC analysis 
For the analysis of the product pattern via high performance liquid chromatography (HPLC), samples 
were extracted twice with two volumes chloroform whereupon the chloroform phase was evaporated 
and the remaining steroids were suspended in acetonitrile for HPLC analysis. Steroids were separated on 
a Jasco reversed phase HPLC system of the LC900 series (Jasco, Groß-Umstadt, Germany) using a 4.6 
mm x 125 mm NucleoDur C18 Isis Reversed Phase column (Macherey-Nagel, Düren, Germany) with 
an acetonitrile/water gradient (Phase A: 10 % acetonitrile in water, Phase B: 100 % acetonitrile; 0 min 
20 % B, 5 min 20 % B, 13 min 40 % B, 20 min 80 % B, 21 min 80 % B, 22 min 20 % B, 30 min 20 % 
B) at 40 °C and a flow rate of 0.8 ml/min. Steroids were detected by an UV/Vis detector (UV-2 075 
Plus, Jasco) at 240 nm (for spironolactone) or 288 nm (for canrenone). 
Spectroscopic binding assay 
The determination of dissociation constants (Kd) was performed by difference spectroscopy in tandem 
cuvettes according to Schenkman [40]. Purified CYP11B1 or CYP11B2 were diluted in a buffer 
consisting of 50 mM potassium phosphate (pH 7.4), 20 % glycerol, 0.5 % sodium cholate and 0.05 % 
Tween 20 to a final concentration of 2 µM and were titrated with increasing amounts of the respective 
substrate dissolved in DMSO and difference spectra were recorded from 350 to 500 nm. To determine 
the Kd, the averaged peak-to-trough absorbance differences from three titrations were plotted against the 
substrate concentration and fitted with hyperbolic regression or tight binding quadratic equation. 
Whole-cell conversion with recombinant E. coli and product purification 
Preparative scale bioconversion was performed with whole E. coli cells containing a functional 
CYP11B2 system by recombinant expression of the P450 cDNA, bovine AdR and truncated bovine 
Adx1-108 from a tricistronic plasmid as previously described for CYP11B1 [30]. Protein expression was 
performed accordingly in 150 mL TB medium per 2 L-Erlenmeyer flask at 27.5 °C and 200 rpm, but 
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expression time was increased to 40 h. Subsequently, cultures were harvested by centrifugation (3200g, 
10 min, 18 °C) and the cell pellet was washed in 50 mM potassium phosphate buffer (pH 7.4). For 
substrate conversion, cells were suspended in 125 ml of 50 mM potassium phosphate buffer (pH 7.4) 
and incubated in a 2 L- Erlenmeyer flask with addition of 1 mM isopropyl β-D-1-thiogalactopyranoside, 
4mg/ml arabinose, 1 mM δ-aminolevulinic acid, 2 % glycerol and 200 µM substrate at 27.5 °C and 200 
rpm for 24 h. Following the conversion time, steroids were extracted twice with 125 ml ethyl acetate. 
The organic phase containing the steroids was concentrated to dryness in a rotatory evaporator. The 
residues were dissolved in acetonitrile and filtered through a sterile syringe filter (0.45 µm). The 
products were separated by preparative HPLC (Jasco reversed phase HPLC system (Jasco, Groß-
Umstadt, Germany), 4.6 mm x 250 mm NucleoDur C18ec column (Macherey-Nagel, Düren, Germany)) 
at 40 °C with acetonitrile/water gradients at 3 mL/min. Steroids were monitored by UV/Vis detection, 
fractions containing the desired products were collected, evaporated to dryness and analyzed by nuclear 
magnetic resonance (NMR) spectroscopy. 
NMR analysis of metabolites 
The NMR spectra were recorded in CDCl3 with a Bruker Avance III 500 NMR spectrometer at 298 K 
using a CPTCI probe head. The chemical shifts were relative to CHCl3 at δ 7.26 (
1H NMR) and CDCl3 
at δ 77.00 (13C NMR) respectively using the standard δ notation in parts per million. The 1D NMR (1H 
and 13C NMR, DEPT135) and the 2D NMR spectra (gs-HH-COSY, gs-NOESY, gs-HSQCED, and gs-
HMBC) were recorded using the BRUKER pulse program library. All assignments were based on 
extensive NMR spectral evidence. 
11β-Hydroxyspironolactone (1). 1H NMR (CDCl3, 500 MHz): δ 1.03 dd (J=11.9 and 3.8 Hz, H-9), 1.24 
s (3xH-18), 1.41 m (H-14), 1.44 m (H-15a), 1.50 s (3xH-19), 1.53 m (H-12a), 1.58 m (H-15b), 1.71 dd 
(J= 13.7 and 2.8 Hz, H-12b), 1.78 m (H-16a), 1.82 m (H-1a), 1.93 ddd (J= 16.3, 9.3 and 7.3 Hz, H-20a), 
2.24 m (H-1b), 2.28 m (2H, H-16b and H-20b), 2.34 m (H-6a), 2.33 s (3xH-24), 2.36 m (H-2a), 2.42 m 
(H-8), 2.45 m (H-21a), 2.47 m (H-2b), 2.55 ddd (J= 17.5, 9.3 and 6.5 Hz, H-21b), 2.94 ddd (J=14.8, 4.2 
and 1.8 Hz, H-6b), 4.08 td (J= 4.2 and 2.8 Hz, H-7), 4.46 q (J=3.4, H-11 Hz) 5.64 s (H-4). 13C NMR 
(CDCl3, 125 MHz): δ 17.23 (CH3, C-18), 21.54 (CH3, C-19), 22.47 (CH2, C-15), 29.23 (CH2, C-21), 
31.24 (CH2, C-20), 31.24 (CH3, C-24), 33.79 (CH2, C-2), 35.02 (CH2, C-16), 35.24 (CH2, C-1), 35.67 
(CH, C-8), 39.38 (C, C-10), 39.51 (CH2, C-6), 40.90 (CH2, C-12), 44.74 (C, C-13), 45.98 (CH, C-7), 
47.09 (CH, C-14), 52.53 (CH, C-9), 67.51 (CH, C-11), 96.02 (C, C-17), 125.41 (CH, C-4), 166.77 (C, 
C-5), 176.49 (C, C-22), 194.13 (C, C-23), 198.80 (C, C-3). 
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18-Hydroxyspironolactone (2). 1H NMR (CDCl3, 500 MHz): δ 1.06 m (H-9), 1.12 m (H-12a), 1.23 s 
(3xH-19), 1.40 m (H-15a), 1.53 m (H-14), 1.55 (H-11a), 1.59 m (H-15b), 1.70 m (H-11b), 1.81 m (H-
1a), 1.94 m (H-20a), 1.97 m (H-16a), 2.07 m (H-16b), 2.08 m (H-8), 2.23 m (H-1b), 2.24 m (2H, H-12b 
and H-20b), 2.34 s (3xH-24), 2.38 m (H-2a), 2.40 m (H-6a), 2.42 m (H-2b), 2.53 m (H-21a), 2.59 m (H-
21b), 2.85 ddd (J=14.8, 4.2 and 2.0 Hz, H-6b), 3.76 d (J=12.5 Hz, H-18a), 3.92 d (J=12.5 Hz, H-18b), 
3.96 td (J= 4.2 and 3.0 Hz, H-7), 5.71 d (J=1.8 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 17.70 (CH3, 
C-19), 20.23 (CH2, C-11), 22.56 (CH2, C-15), 26.62 (CH2, C-12), 28.34 (CH2, C-21), 31.04 (CH2, C-
20), 31.34 (CH3, C-24), 33.88 (CH2, C-2), 35.53 (CH2, C-1), 35.62 (CH2, C-16), 38.52 (C, C-10), 
38.60 (CH, C-8), 39.89 (CH2, C-6), 45.03 (CH, C-7), 45.90 (CH, C-14), 48.94 (C, C-13), 49.56 (CH, C-
9), 60.94 (CH2, C-18),  96.94 (C, C-17), 127.07 (CH, C-4), 165.32 (C, C-5), 176.68 (C, C-22), 194.22 
(C, C-23), 198.66 (C, C-3). 
19-Hydroxyspironolactone (3). 1H NMR (CDCl3, 500 MHz): δ 1.00 s (3xH-18), 1.09 m (H-9), 1.28 m 
(H-12a), 1.35 m (H-14), 1.39 m (H-15a), 1.56 m (H-15b), 1.59 (H-11a), 1.60 m  (H-12b), 1.73 m (H-
16a), 1.75 m (H-11b), 1.76 m (H-1a), 1.94 m (H-20a), 2.24 m (H-20b), 2.25 m (H-8), 2.32 m (2H, H-1b 
and H-16b), 2.34 s (3xH-24), 2.35 m (H-2a), 2.48 m (2H, H-6a and H-21a), 2.55 m (H-21b), 2.64 m (H-
2b), 2.97 ddd (J=14.6, 4.2 and 2.0 Hz, H-6b), 3.95 d (J=10.3 Hz, H-19a),  4.01 td (J= 4.2 and 3.0 Hz, H-
7), 4.04 d (J=10.3 Hz, H-19b), 5.90 d (J=1.8 Hz, H-4). 13C NMR (CDCl3, 125 MHz): δ 14.70 (CH3, C-
18), 20.90 (CH2, C-11), 22.19 (CH2, C-15), 29.18 (CH2, C-21), 31.15 (CH2, C-20), 31.35 (CH3, C-24), 
31.59 (CH2, C-12), 33.63 (CH2, C-1), 34.71 (CH2, C-2), 35.20 (CH2, C-16), 39.78 (CH, C-8), 41.07 
(CH2, C-6), 43.12 (C, C-10), 45.11 (CH, C-7), 45.60 (C, C-13), 46.51 (CH, C-14), 49.78 (CH, C-9), 
66.40 (CH2, C-19),  95.50 (C, C-17), 129.58 (CH, C-4), 162.27 (C, C-5), 176.52 (C, C-22), 194.31 (C, 
C-23), 198.94 (C, C-3). 
11β-Hydroxycanrenone (5). 1H NMR (CDCl3, 500 MHz): δ 1.19 dd (J=10.3 and 3.2 Hz, H-9), 1.30 s 
(3xH-18), 1.32 m (H-14), 1.69 m (H-15a), 1.37 s (3xH-19), 1.56 dd (J= 13.7 and 3.0 Hz, H-12a), 1.89 m 
(H-15b), 1.73 dd (J= 13.7 and 2.8 Hz, H-12b), 1.83 m (H-1a), 1.87 m (H-16a), 1.92 m (H-20a), 2.23 ddd 
(J= 12.8, 5.3 and 2.3 Hz, H-1b), 2.34 m (H-16b), 2.47 m (H-2a), 2.76 t (J= 11.0 Hz, H-8), 2.48 dd (J= 
9.3 and 7.5 Hz, H-21a), 2.56 dd (J= 9.3 and 6.3 Hz, H-21b), 2.63 ddd (J= 17.5, 14.5 and 5.3 Hz, H-2b), 
2.27 ddd (J= 13.0, 6.9 and 2.9 Hz, H-20b), 4.08 td (J= 4.2 and 2.8 Hz, H-7), 4.47 q (J=3.4 Hz, H-11) 
5.64 s (H-4), 6.14 dd (J=9.8 and 2.0 Hz, H-7), 6.16 brd (J=9.8 Hz, H-6). 13C NMR (CDCl3, 125 MHz): δ 
16.97 (CH3, C-18),18.97 (CH3, C-19), 22.66 (CH2, C-15), 29.27 (CH2, C-21), 31.52 (CH2, C-20), 
33.19 (CH2, C-1), 33.86 (CH2, C-2), 34.09 (CH, C-8), 35.37 (CH2, C-16), 36.44 (C, C-10), 40.79 
(CH2, C-12), 45.98 (C, C-13), 48.38 (CH, C-14), 53.33 (CH, C-9), 67.17 (CH, C-11), 95.77 (C, C-17), 
122.88 (CH, C-4), 128.10 (CH2, C-6), 139.89 (CH, C-7), 164.06 (C, C-5), 176.51 (C, C-22), 199.55 (C, 
C-3). 
2.4 Müller and Schiffer et al. 2015, under review 
 
85 
 
18-Hydroxycanrenone (7). 1H NMR (CDCl3, 500 MHz): δ 1.13 s (3xH-19), 1.18 td (J= 12.5 and 4.0 Hz, 
H-12a), 1.25 ddd (J=13.0, 10.3 and 3.7 Hz, H-9), 1.48 m (H-14), 1.53 (H-11a), 1.54 m (H-15a), 1.71 m 
(H-11b), 1.72 m (H-1a), 1.91 m (H-15b), 1.95 m (H-20a), 2.02 m (H-16a), 2.04 m (H-2a), 2.31 dt (J= 
12.5 and 3.3 Hz, H-12b), 2.36 m (H-8), 2.40 m (H-20b), 2.41 m (H-16b), 2.46 m (H-2b), 2.55 m (H-
21a), 2.58 m (H-1b), 2.60 m (H-21b), 3.84 d (J=12.5 Hz, H-18a), 3.95 d (J=12.5 Hz, H-18b), 5.69 s (H-
4), 6.05 dd (J=9.8 and 2.0 Hz, H-7), 6.14 dd (J=9.8 and 2.7 Hz, H-6). 13C NMR (CDCl3, 125 MHz): δ 
16.66 (CH3, C-19), 19.85 (CH2, C-11), 22.71 (CH2, C-15), 26.61 (CH2, C-12), 28.45 (CH2, C-21), 
31.14 (CH2, C-20), 33.92 (CH2, C-2), 33.96 (CH2, C-1), 35.89 (CH2, C-16), 36.11 (C, C-10), 37.41 
(CH, C-8), 47.02 (CH, C-14), 49.67 (C, C-13), 50.53 (CH, C-9), 60.71 (CH2, C-18),  96.86 (C, C-17), 
124.20 (CH, C-4), 128.70 (CH2, C-6), 138.71 (CH, C-7), 162.76 (C, C-5), 175.74 (C, C-22), 199.45 (C, 
C-3). 
11β,18-Dihydroxycanrenone (8). 1H NMR (CDCl3, 500 MHz): δ 1.18 ddd (J=β.0 and 2.7 Hz, H-9), 1.36 
m (H-12a), 1.40 s (3xH-19), 1.47 m (H-14), 1.62 m (H-15a), 1.83 m (H-1a), 1.98 m (2H, H-15b and H-
20a), 2.04 m (H-16a), 2.31 m (H-1b), 2.32 m (H-20b), 2.42 m (H-12b), 2.44 m (H-16b), 2.50 m (H-2a), 
2.54 dd (J= 9.0 and 6.3 Hz, H-21a), 2.61 m (J= 9.0 and 7.5 Hz, H-21b), 2.65 ddd (J= 17.5, 14.5 and 5.4, 
H-2b), 2.89 t (J= 11.0 Hz, H-8), 3.97 m (J=12.0 Hz, H-18a), 4.13 d (J=12.0 Hz, H-18b), 4.43 q (J= 3.2 
Hz, H-11), 5.64 s (H-4), 6.11 brd (J=9.8 Hz, H-7), 6.13 dd (J=9.8 and 2.0 Hz, H-6). 13C NMR (CDCl3, 
125 MHz): δ 18.68 (CH3, C-19), 22.79 (CH2, C-15), 28.72 (CH2, C-21), 31.42 (CH2, C-20), 33.22 
(CH2, C-1), 33.84 (CH, C-8), 33.86 (CH2, C-2), 34.44 (CH2, C-12), 35.90 (CH2, C-16), 36.52 (C, C-
10), 47.88 (CH, C-14), 49.20(C, C-13), 53.73 (CH, C-9), 62.89 (CH2, C-18),  66.02 (CH2, C-11), 96.61 
(C, C-17), 123.08 (CH, C-4), 128.36 (CH2, C-6), 139.15 (CH, C-7), 163.84 (C, C-5), 175.84 (C, C-22), 
199.64 (C, C-3). 
MR transactivation assay 
The cell culture-based reporter assay was performed using the Human MR Reporter Assay System (96-
well Format Assays) from Indigo Biosciences. The assay was carried out according to the 
manufacturer’s protocol (Technical manual (Version 7.1.)). For the antagonist mode, aldosterone was 
added in its median effective concentration (EC75) of 333 pM. The test compounds were added in a 
concentration of 20 nM corresponding to the IC50 of spironolactone according to the manufacturer. The 
statistics were performed using student’s t-test with unpaired samples as two sided test and a 
significance level of p <0.05. For the agonist mode, all compounds were applied individually with a 
concentration of 333 pM (EC75 of aldosterone). 
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Results and discussion 
CYP11B1- and CYP11B2-dependent in vitro-conversion of MRAs 
In-vitro reconstitution assays were performed using the respective purified P450, human Adx and AdR 
in a molar ratio of 1:20:1 to ensure maximal enzyme activity [41-43]. Product formation was monitored 
by HPLC with UV/vis detection, whereby products with the same retention time were assumed to be the 
same compounds. Spironolactone and canrenone were successfully metabolized by CYP11B1 and 
CYP11B2 despite of their structural divergencies from the natural substrates, which comprise the 
carbolactone at C17 for both MRAs and the polar thioacetyl group at C7 in α-orientation for 
spironolactone. The conversion of spironolactone by both isoforms led to similar product patterns 
showing one major metabolite (1) and two side products (metabolites 2 and 3) (Fig. 1A and B). For 
canrenone, which is smaller than spironolcatone, due to the removal of the 7α-thioacetyl group, isoform-
specific product formation can be observed. Canrenone is metabolized to three products by CYP11B1 
and five products by CYP11B2 (Fig. 1C and D). Thereby, metabolites 5, 6 and 7 are derived from both 
P450s, while metabolites 4 and 8 are specific for CYP11B2. This reflects the larger reaction capacity of 
CYP11B2 compared with CYP11B1 [8], which seems, however, to be restricted to smaller substrates.  
No conversion of the third MRA, eplerenone, by any of the two isozymes could be observed 
(chromatogramm not shown). Additionally, spectroscopic binding assays revealed no spin state changes 
for CYP11B2 upon titration of eplerenone suggesting no binding to the active site (spectra not shown). 
We suppose that the 9,11α-epoxid of eplerenone hampers the binding and conversion of this MRA. The 
crystal structure of CYP11B2 revealed that proper binding of its substrates is ensured, besides hydrogen 
bonding, by hydrophobic interactions of the substrate’s α-face with aromatic amino acid side chains 
lying opposite to the heme [44]. The presence of the α-epoxy group interferes with these interactions.  
Taken together, our data show that the pharmaceutically relevant steroids spironolactone and canrenone 
can undergo biotransformation by CYP11B1 and CYP11B2, which strengthens the presumption of the 
participation of these adrenal P450s in xenobiotic metabolism. Hereby, the substrate acceptance depends 
on the conservation of key structures of the substrate for recognition and binding by the CYP11B 
isoenzymes like the 3-keto-∆4 motif and the degree and distribution of α-face polarity.  
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Fig. 1: HPLC chromatograms of the in-vitro conversion of spironolactone and canrenone by 
CYP11B1 and CYP11B2. A - spironolactone conversion by CYP11B1 with enlargement of metabolite 
3 in the inset; B - spironolactone conversion by CYP11B2; C - canrenone conversion by CYP11B1; D - 
canrenone conversion by CYP11B2. The dotted lines show the respective negative control without 
NADPH. Reactions were performed for 1 h at 37 °C in 50 mM HEPES pH 7.4 supplemented with 20 % 
glycerol and 100 µM 1,2-didodecanoyl-sn-glycero-3-phosphocholine and the respective substrate in a 
concentration of 400 µM, using 0.5 µM CYP11B1 or CYP11B2, 0.5 µM AdR and 10 µM Adx. 
Extracted steroids were monitored at a wavelength of 240 nm or 288 nm for spironolactone and 
canrenone, respectively. 
Determination of dissociation constants (Kd) of spironolactone and canrenone 
For comparison of the binding affinities of the new exogenous substrates with the natural substrates of 
gluco- and mineralocorticoid biosynthesis, dissociation constants were determined by UV/vis-
spectroscopy. All substances induce a high-spin shift of the heme iron (Fig. 2, insets), which enables the 
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determination of a Kd value using the type-I difference spectrum upon substrate titration to the P450. All 
values are summarized in Table 1. 
Except for the binding of canrenone by CYP11B1, all Kd values for the investigated substrates are 
slightly higher but in the same order of magnitude than those for the natural substrates, DOC and RSS. 
The structural differences do, thus, not significantly influence the binding properties. CYP11B1 shows 
weaker binding of DOC than of RSS, which matches the deviations in the catalytic efficiency for the 
two substrates [11] and demonstrates a positive contribution of the 17α-OH group for substrate binding.  
Although spironolactone is larger than canrenone and additionally differs from the natural substrates by 
the 7α-thioacetyl function, it exhibits a higher affinity for both CYP11B isoforms suggesting that either 
the size of the molecule promotes binding or the additional group itself enhances the affinity through 
new interactions. Furthermore, it is remarkable that CYP11B2 shows a higher affinity for both 
exogenous substrates than CYP11B1. This can be explained by the increased intrinsic flexibility and 
thus adaptability for foreign substrates, which has been postulated for CYP11B2 as a result of its 
isoform-specific residues around the H- and I-helices [44].  
 
Table 1: Dissociation constants (Kd) of CYP11B1 and CYP11B2 for their endogenous and 
exogenous substrates. Values were determined by difference spectroscopy and regression of the 
absorbance shift as shown in Fig. 2. Regression coefficients (R2) are indicated. n.d. = not determined. 
 CYP11B1 CYP11B2 
Substrate Kd [µM] R
2 Kd [µM] R
2 
Canrenone 72.5 ± 9.2 0.99 5.5 ± 0.4 0.99 
Spironolactone 9.3 ± 0.7 0.99 4.1 ± 0.4 0.98 
DOC 8.1 ± 0.5 0.99 1.3 ± 0.1 [9] 0.99 [9] 
RSS 6.6 ± 0.4 0.99 n.d. n.d. 
Corticosterone n.d. n.d. 115 ± 6 [9] 0.99 [9] 
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Fig. 2: Determination of CYP11B1 and CYP11B2 affinity for their substrates by difference 
spectroscopy and regression of the absorbance shift. CYP11B1 with canrenone (A), spironolactone 
(B), 11-deoxycortisol (C) and 11-deoxycorticosterone (D), CYP11B2 with canrenone (E) and 
spironolactone (F). 2 µM of the P450 were titrated in tandem cuvettes with increasing concentrations of 
the respective substrate from a stock solution in DMSO and difference spectra were recorded from 350-
500 nm (insets). The peak-to-trough differences of the absorbance were plotted against the substrate 
concentrations and fitted as described in Material & Methods for the determination of the Kd. 
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Effect of spironolactone and canrenone on CYP11B1- and CYP11B2-dependent substrate 
conversions 
The binding and conversion of spironolactone and canrenone by the two CYP11B isoforms suggests an 
effect on their natural function by a competition of the endogenous and exogenous substrates for the 
active site. We, therefore, evaluated the effect of spironolactone and canrenone on the conversion of 
RSS, the substrate for glucocorticoid synthesis, by CYP11B1 and the conversion of the aldosterone 
precursor DOC by CYP11B2 (Fig. 3). Natural substrate concentration was kept below the saturation at 
20 µM and the respective MRA was added in two-fold excess, as plasma levels of spironolactone and 
canrenone can exceed RSS and DOC levels already after a single oral dose [22, 45-47]. Product 
formation from spironolactone and canrenone was not detectable due to the short reaction time. 
Spironolactone showed no significant effect on CYP11B2 activity, while it reduced CYP11B1-
dependent conversion of RSS from 68 to 43 %. These differential effects on the two isoforms correlate 
well with their affinities for the natural substrates. CYP11B2 tightly binds DOC with a Kd of 1.3 µM, 
while the Kd for spironolactone is four-fold higher [9]. CYP11B1, in contrast, shows a higher Kd of 6.6 
µM for its substrate RSS and a Kd of 9.3 µM for spironolactone and its conversion is, therefore, more 
susceptible to an interference by spironolactone. The presence of canrenone did not affect the activity of 
CYP11B1 thereby reflecting its high Kd value. Surprisingly, canrenone, whose Kd for CYP11B2 is 
higher when compared with spironolactone, exhibited an inhibitory effect on CYP11B2 and decreased 
DOC conversion from 97 to 73 %. This might be due to an additional non-competitive inhibitory effect 
of canrenone. 
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Fig. 3: Influence of spironolactone and canrenone on natural substrate conversion by CYP11B1 
(A) and CYP11B2 (B) in the reconstituted in-vitro system. The system consisted of 0.25 μM CYP,  
5 μM Adx and 0.25 μM AdR, 1 mM NADPH and an NADPH regenerating system and the reaction took 
place at 37 °C for two minutes. The substrate concentration was 20 µM to be below saturation and 
spironolactone or canrenone were added in two-fold excess (40 µM). Substrate conversion was 
determined by HPLC with progesterone as internal standard. Values represent the mean of three 
reactions with standard deviation. 
Metabolite production by whole-cell catalysis with E. coli  
Preparative scale production of the new MRA metabolites for purification and characterization was 
performed with recombinant E. coli cells containing a functional P450 system by co-expression of 
CYP11B2, bovine AdR and bovine Adx1-108 as previously described for CYP11B1 [30]. The auxiliary 
overexpression of the two E. coli chaperones GroEL and GroES ensured correct folding of the enzymes. 
Substrate conversion took place in potassium phosphate buffer after the transfer of the cells into a 
resting state for a better NADPH availability [48] and a reduction of the production of E. coli 
metabolites that could impede purification. HPLC analysis revealed the same product patterns of 
canrenone and spironolactone conversion as with the purified enzymes (see Figs. 1 and 4). For 
canrenone, the most polar metabolite 8 is produced in a greater portion than in-vitro, which can be a 
result of a prolonged functionality of the P450 system enabled by the cellular environment or a redox 
partner ratio, which is beneficial for the advancement of the reaction. For spironolactone, all three 
metabolites were purified. In case of canrenone, only the major metabolites 5, 7 and 8 were produced in 
sufficient amounts for subsequent NMR studies. 
Canrenone and spironolactone were converted with approximate volumetric productivities of 51 and 55 
mg*L-1*d-1, respectively. The presented whole-cell system is thus an attractive tool to efficiently 
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produce the CYP11B2-derived metabolites on a preparative scale. As pharmaceutical steroids are widely 
applied for the treatment of multiple medicinal issues and an increasing number of them is identified as 
substrate for steroidogenic P450s, the preparation of their metabolites for the characterization of their 
bioactivity will gain increasing interest. 
Fig. 4: HPLC chromatogram of the CYP11B2-dependent conversion of spironolactone (A) and 
canrenone (B) with an E. coli whole-cell system. E. coli C43(DE3) cells expressing human CYP11B2, 
bovine AdR and Adx1-108 were employed in resting-cell modus for the bioconversion of 200 µM MRA 
in potassium phosphate buffer for 24 h.  
Structure elucidation by NMR 
Spironolactone was biotransformed into three products 1-3. The NMR data of 1 revealed resonances for 
a secondary hydroxyl group (δH 4.46 q, J= 3.4 Hz; δC 67.51, CH). Its position at C-11 could be deduced 
from correlations of its proton with H-9 (1.03 dd, J=11.9 and 3.8 Hz), H-12a (1.53 m) and H-12b 
(J=1.71 dd, 13.7 and 2.8 Hz) in the HHCOSY. The coupling pattern of H-11 with coupling constants < 4 
Hz gave hint to an equatorial position and H-11 is therefore β-oriented. As a consequence, the hydroxyl 
group at C-11 must be axial and in β-configuration. In contrast to spironolactone, its conversion 
products 2 and 3 both lacked one methyl group. Therefore, the resonances of a primary alcohol appeared 
in their NMR spectra (2: δH 3.76 and 3.92, both d, δC 60.94, CH2; 3: δH 3.95 and 4.04, both d, δC 
66.40, CH2). HMBC correlations between the alcoholic protons and their geminal and vicinal carbons 
revealed the presence of 18-OH-spironolactone for compound 2 and 19-OH-spironolactone for 
compound 3.  
The separation of the canrenone biotransformation products led to the isolation and structure elucidation 
of three conversion products, 5, 7 and 8, of which two were mono-alcohols and one was a 
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dihydroxylated compound. The NMR data of 5 resembled those of compound 1, especially for the 
secondary alcohol function (δH 4.47 q, J= 3.4 Hz; δC 67.17, CH). This led to the structure of 11β-OH-
canrenone for compound 5, which could be proved by 2D NMR measurements. 11β-OH-canrenone is 
not known so far, in contrast to its 11β-epimer, which is the main product in the biotransformation of 
canrenone by Aspergillus ochraceus SIT34205 [49] and the key intermediate in the synthesis of the 
cardiovascular drug eplerenone [50]. The NMR spectra of 7 indicated the presence of 18-OH-canrenone. 
The former methyl group at C-18 of the substrate was replaced by a primary alcohol function. Its 
chemical shifts (δH 3.84 and 3.95, both d, δC 60.71, CH2) were very close to those of the correspondent 
spironolactone product 2. Compound 8 was found to be a diol (δC 62.89, CH2; δC 66.02, CH). The 
proton shifts of the hydroxyl groups showed a combination of the properties as found in 5 and 7 and 
gave rise to a hydroxylation in position 11β (δH 4.43 q, J= 3.2 Hz,) and at C-18 (δH 3.97 and 4.13, both 
dd, both J=12.0 Hz). 2D NMR supported these findings and let to the full assignment of 11β,18-di-OH-
canrenone. 
Taken together, NMR analysis revealed that canrenone is metabolized to 11β- (metabolite 5) and 18-
OH-canrenone (metabolite 7) by both isozymes and to the CYP11B2-specific metabolite 11β,18-di-OH-
canrenone (8). Spironolactone is converted to three mono-hydroxylated metabolites: 11β-OH- (1), 18-
OH- (2) and 19-OH-spironolactone (3). Reactions are illustrated in Fig. 5. They target the same 
positions as for the natural substrates DOC and RSS [8], which correlates with the steroidal nature of 
canrenone and spironolactone and the presence of the 3-keto-∆4 motif which is conserved among all 
known steroidal CYP11B substrates. These features ensure a binding mode of canrenone and 
spironolactone similar to that of the natural substrates. For both substrates, the major metabolite is the 
11β-hydroxylated derivative, whose formation is also sterically and energetically favored for DOC [9, 
44]. However, the total reaction repertoire differs between the two MRAs. Contrary to spironolactone, 
canrenone can also be di-hydroxylated by CYP11B2 and the total amount of products formed from 
canrenone, including the two side products, is higher than for spironolactone. The reduction in size of 
canrenone compared with spironolactone obviously enables a longer retention time and the movement in 
the active site and, thus, a second hydroxylation as well as the targeting of additional positions of the 
steran scaffold. For both MRAs, no oxidation of the hydroxyl to the corresponding aldehyde, as it is 
introduced by CYP11B2 at C18 during the formation of aldosterone, could, however, be demonstrated. 
This oxidation is assumed to occur processively and to require the retention of the intermediate [8, 9, 
44], which seems not to be permitted for the MRAs. 
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Fig. 5: Metabolism of MRAs catalyzed by CYP11B1 and CYP11B2. Metabolites were characterized 
by NMR after whole-cell production with recombinant E. coli.  
Influence of MRA metabolites on MR transactivation 
The metabolism of drugs can significantly alter or even reverse their bioactivity. Metabolite 
identification and studies of their toxicity and influence on the initial drug target are thus crucial for the 
development of efficient pharmaceuticals and the reduction of adverse effects. Spironolactone and 
canrenone target the MR, a key regulator of blood pressure, by blocking its aldosterone-mediated 
activation, which promotes their antihypertensive effects. MR activation depends on the development of 
a specific ligand-mediated hydrogen bond network, involving the residues Asn770 and Thr945, for the 
introduction of conformational changes inducing chaperone release, translocation into the nucleus and 
the transcription of target genes. The structure of the hydrogen bond network and, as a consequence, 
receptor activation or its prevention can be altered by oxofunctionalization of the ligands at positions C3, 
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C11, C17, C18, C20 and C21 [51-53]. Spironolactone is described as a “passive” MR antagonist. It binds 
inside the ligand binding pocket, but fails to build hydrogen bonds to Asn770 and Thr945 and in this 
way prevents the transition to the active conformation [51]. Therefore, we studied the MR antagonist 
potential of the newly identified MRA metabolites using a commercially available transactivation assay, 
which enables a relative quantification of the MR activity by luciferase derived luminescence. 
Aldosterone was applied in its EC75 and all test compounds were added in a concentration that 
corresponds to the IC50 of spironolactone (manufacturer’s technical manual). Compared to the vehicle 
control, the presence of aldosterone alone leads to MR activation, which is specifically modulated by 
spironolactone, canrenone and their metabolites (Fig. 6). As can be expected according to the manual, 
spironolactone inhibits aldosterone-induced MR activation by approximately 50 %. The same extend of 
antagonist effect can be observed for canrenone. Interestingly, 11β-OH-spironolactone is the only 
metabolite that shows an antagonist effect comparable to the parent compounds and can be introduced as 
new putative pharmaceutically active metabolite of spironolactone. In case of canrenone, the 11β-
hydroxylation abolishes the antagonist effect, which hints at a role of the combination with the opposite 
7α-thioacetyl function for the antagonist retaining effect of the 11β-hydroxyl group. All other 
metabolites show a reduced MR antagonist activity, whereby the two 18-mono-hydroxylated 
metabolites, 18-OH-spironolactone and 18-OH-canrenone, even exhibit slight agonist properties. 
However, all compounds did not demonstrate MR activation when applied individually in an agonist 
mode assay at a concentration of the EC75 of aldosterone (data not shown). It is likely that the agonist 
effect of the 18-OH metabolites observed in the antagonist mode assay results from unspecific binding 
that supports aldosterone activity by long-range effects. 
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Fig. 6: Antagonist mode MR-transactivation assay with MRAs and the CYP11B-derived 
metabolites of spironolactone (Spiro) and canrenone (Can). Each compound was analyzed for its 
antagonist potential with INDIGO Bioscience Human Mineralocorticoid Receptor Reported Assay 
System following the manufacturer’s protocol at a concentration of 20 nM (IC50 spironolactone), 
whereby aldosterone was added as agonist at its EC75 to all mixtures. Values represent the luminescence 
signal of MR-responsive luciferase reporter gene expression and were normalized to vehicle control.  
–MRA shows the aldosterone-mediated MR activation in absence of an antagonist. The assay was 
performed with n=5 for each compound. Statistical evaluation was performed using student’s t-test with 
unpaired samples as two sided test: * p<0.05, ** p<0.01, *** p<0.001. 
Conclusions 
This work confirms the potential of the human steroid hormone synthesizing CYP11B1 and CYP11B2 
to carry out the biotransformation of the xenobiotic steroids spironolactone and canrenone, which are 
frequently applied pharmaceuticals for the treatment of hypertension because of their MR antagonist 
features. The CYP11B-dependent metabolism of the MRAs abolishes this action, as all metabolites, 
except for 11β-OH-spironolactone, show reduced or completely voided MR antagonist properties. 
Therefore, we suggest that steroidogenic P450s should be considered, in addition to the liver isoforms, 
as drug-metabolizing enzymes, who can significantly modulate the bioactivity of a drug. 
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3. Discussion & conclusions 
3.1 Insights into the pharmacokinetic potential of steroidogenic P450s 
3.1.1 Selected AAS are metabolized by particular steroidogenic P450s. 
In this work, the potential of steroidogenic P450s to convert exogenous compounds was initially studied 
by taking the example of anabolic androgenic steroids (AAS), which is presented in publication 2.3. 
Because of their performance enhancing effects via the activation of the androgen receptor (AR), 
anabolic agents, and in particular AAS, are widely misused for doping purposes in all sports by 
professional and recreational athletes. In doping controls, they represent the most frequently detected 
class of substances prohibited by the World Anti-Doping Agency (WADA) (WADA, 2015). AAS are 
synthetic derivatives of the natural androgen testosterone, which are chemically modified to favor 
anabolic effects, reduce androgenic effects and alter distribution and metabolism (Fragkaki et al., 2009). 
After intake and resorption, AAS as well as other drugs or xenobiotics undergo extensive phase I- and 
phase II-metabolism in the liver, which includes biotransformations by hepatic, microsomal P450s of the 
CYP1, 2 and 3 families. Therefore, structural modifications were developed to reduce the first-pass 
metabolism of AAS in the liver and provide oral availability and prolongation of the anabolic effect 
(Fragkaki et al., 2009). Thereby, 17α-alkylation is an efficient modification to enhance the stability 
towards hepatic metabolism. All three compounds tested in this work (oral-turinabol (OT), oxandrolone 
and stanozolol) carry a 17α-methyl group as can be seen from the structural formula presented in Figure 
3.1. Additionally, the A-ring is modified by the introduction of a double bond and a substituent (oral-
turinabol, OT), heteroatom replacement (oxandrolone), junction with a pyrazole ring (stanozolol) and 
reduction of the ∆4 double bond to 5α configuration (oxandrolone, stanozolol), which enhances AR 
binding and hence anabolic activity. The reduced first-pass metabolism in the liver, conclusively, leads 
to high levels of the parent drug in the blood and raises the question for alternative metabolic paths at 
extrahepatic sites. In this context, P450s of the CYP11, 17, 19 and 21 families, which contribute to the 
biosynthesis of steroid hormones in the adrenal cortex and reproductive tissues, are interesting target 
enzymes for further investigations due to the structural similarity of their natural substrates to AAS. All 
six steroidogenic P450s were hence assayed in this work for the conversion of the three selected AAS. 
 
3. Discussion 
 
117 
 
 
Figure 3.1: Structural formula of AAS tested for metabolism by human steroidogenic P450s. 
OT was demonstrated to be converted by all three human mitochondrial steroidogenic P450s 
(CYP11A1, CYP11B1 and CYP11B2), whereby 2-OH-OT (suggested to be 2β-OH-OT), 11β-OH-OT, 
11β,18-diOH-OT and 11β-OH-OT-18-al emerged as new OT derivatives that have to date not been 
described in the literature and, thus, not been tested for bioactivity and analytical application. No 
metabolism of OT by CYP17A1, CYP19A1 and CYP21A2 could be observed. Oxandrolone and 
stanozolol were not metabolized by any of the P450s. This leads to the conclusion that steroidogenic 
P450s are capable of converting xenobiotic steroids, but catalysis requires the conservation of general 
and P450-specific core motifs to enable the binding of the steroid in the active site and to present a 
target atom for oxygen incorporation in close proximity over the heme. These are a 3-keto-∆4 or 3-OH-
∆5 motif, which are present in all natural steroid intermediates and permit hydrogen bonding to specific 
residues in the active site (Ghosh et al., 2009; Strushkevich et al., 2011; Strushkevich et al., 2013; 
Petrunak et al., 2014; Pallan et al., 2015). For oxandrolone and stanozolol the absence of such a motif 
seems to prevent catalysis. The crystal structures of human CYP17A1 and CYP21A1 revealed a 
perpendicular binding of the natural substrates relative to the heme, which renders the C17 and C20 or C21 
atom available over the heme iron for oxygen incorporation (Petrunak et al., 2014; Pallan et al., 2015). 
Due to its 3-keto-∆4 motif, OT is likely to bind in a mode comparable to the natural substrates, but it 
lacks the C20-C21 side chain in β position and is, thus, placed too far from the heme to interact with the 
activated oxygen. This is consistent with the results published by Parr et al., who did not observe a 
conversion of metandienone, another 17β-OH-17α-methyl AAS, by CYP17A1 and CYP21A2 (Parr et 
al., 2012). In case of CYP19A1, the reaction mechanism is proposed to be initiated by the abstraction of 
the hydrogen in position 2β and 2,3-enolization of the substrate (Ghosh et al., 2009). The absence of a 
hydrogen in position 2β and the presence of Cl at position 4 in the same plane as the 3-keto group might 
hinder this initiation. Taken together, the insights from crystal structures explain that CYP11B1 and 
CYP11B2 have the greatest potential for the conversion of AAS and similar exogenous steroids. The 
crystal structure of CYP11B2 in complex with DOC revealed a binding of the substrate parallel to the 
heme (Strushkevich et al., 2013). A comparable orientation of the substrate in the active site of 
CYP11B1 can be assumed due to the high sequence identity to CYP11B2 and their consistent 
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selectivity. The parallel binding mode makes the substrate likely to be placed close enough over the 
heme for catalysis independent from its size. 
3.1.2 OT products derived from metabolism by the CYP11 family constitute interesting 
compounds for preventive doping research. 
As introduced above, anabolic agents are prohibited, but popular performance enhancing drugs and 
constitute, with 48 % in 2014, the most adverse analytical findings (WADA, 2015) reported by WADA 
accredited laboratories. The evidence of a doping delict is commonly provided by the detection of 
urinary metabolites by chromatographic/mass spectrometric techniques (Geyer et al., 2014; Schänzer 
and Thevis, 2015). However, the prolongation of the detection window, which is required for a better 
retrospective conviction, is a great challenge. It can be approached by an improvement of the analytical 
screening procedure and by the discovery of new long-term metabolites (LTMs), whose incorporation 
into routine screening regularly leads to great increases in the number of adverse analytical findings 
(Geyer et al., 2014). The search for new metabolites is commonly conducted by chemical synthesis of 
reference compounds and comparison with the metabolic profile of biological matrices after 
administration by mass spectrometric methods. An alternative, which was chosen for this work, is the 
incubation of the parent compound with a system containing the human enzymes suggested to contribute 
to metabolism. These can be human tissue homogenates, whose availability is, however, limited, 
recombinant expression systems like insect cell cultures (Rendic et al., 1999), microorganisms (Zöllner 
et al., 2010b) or purified enzymes. The utilization of recombinant systems additionally enables the 
identification of the biocatalyst responsible for the transformation, which gives basic insights into 
pharmacokinetics and enzymatic properties. Studies with recombinant insect cells and purified enzymes 
could identify CYP3A4 as 6β-hydroxylase of OT (Rendic et al., 1999). A variety of AAS modifications 
occurring during the phase-I metabolism have been elucidated since the 1960s. Hydroxylation in 
positions 6β, 16α, 16β and 12 are described (Schänzer and Donike, 1993; Schänzer et al., 1995; 
Schänzer, 1996; Schänzer et al., 1996), whereby the 6β-hydroxylation seems to be the major metabolic 
pathway for OT (Schänzer et al., 1995). CYP11A1, which was identified in this work as additional 
putative 6- and 16-hydroxylase for OT, could contribute to the production of these metabolites, as it is 
expressed in all steroidogenic tissues, but also in the gastrointestinal tract (Guo et al., 2003), where it 
comes into contact with orally administered compounds. Subsequent to 16-hydroxylation, an oxidation 
to the 16-ketone can take place. Further modifications are a 3α-/3β-hydroxy-reduction of the 3-ketone, 
whereby the 3α-isomer emerges for all 17β-hydroxy-17α-methyl AAS, a 5α-/5β-reduction with an 
isomer ratio depending on the individual structure of the AAS, hydrogenation of double bonds, 
interconversion of a 17β-hydroxy group to the 17-ketone and epimerization of 17β-hydroxy-17α-methyl 
AAS (Schänzer, 1996). Only in 2006, 17β-hydroxymethyl-17α-methyl-18-norandrost-13-ene derivatives 
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were discovered as a new group of LTM of several 17-methylated AAS including OT, which can 
enlarge the detection window up to ~20 days and more if used as target metabolite (Schänzer et al., 
2006; Parr et al., 2010; Sobolevsky and Rodchenkov, 2012). The phase-I metabolism of OT is 
schematically summarized in Figure 3.2 in comparison with the products characterized in this work.  
 
 
Figure 3.2: Summary of phase-I metabolism of OT described in the literature in comparison with 
the new derivatives from this work. (A) Indication of modifications identified as reviewed by 
(Schänzer, 1996). (B) General structure of novel LTMs discovered between 2006 and 2012 (Schänzer et 
al., 2006; Parr et al., 2010; Sobolevsky and Rodchenkov, 2012), which share a 17β-hydroxymethyl-17α-
methyl-18-norandrost-13-ene structure (highlighted in red) combined with different A-ring 
modifications indicated in (A). (C) OT derivatives identified in this work with new modifications 
highlighted by blue frames.  
The new OT derivatives differ from all metabolites described so far and, thus, constituted interesting 
candidates for an evaluation as putative target metabolites for doping controls. Therefore, urine samples 
of a volunteer collected 6, 24 and 96 h after oral administration of a single dose of 5 mg OT were 
surveyed for the presence of the new OT derivatives by LC- and GC-tandem mass spectrometry as 
described in 5.1.1. Experiments were carried out by the Center for Preventive Doping Research at the 
German Sport University Cologne. Unfortunately, none of the compounds could be detected. As the 
timeframe of urine collection is considered as sufficient for a detection of all metabolites, which are 
excreted via the kidney, it is suggested that other modifications hampering the detection are introduced 
prior or subsequent to the putative in-vivo turnover by CYP11A1, CYP11B1 and CYP11B2. These 
modifications could include 5β-reduction, 3α-hydroxy-reduction and additional hydroxylations, as 
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described above as common reactions of OT metabolism, but also an oxidation of the new 11β-hydroxyl 
to its ketone by an 11β-hydroxy steroid dehydrogenase (11β-HSD). Moreover, a Wagner-Meerwein 
rearrangement subsequent to the CYP11B2-dependent biotransformation could lead to the formation of 
11β-hydroxy-17,17-dimethyl-18-nor-13-ene and 11β-hydroxy-17β-hydroxymethyl-17α-methyl-18-nor-
13-ene products (Parr et al., 2012). Comparably, endogenous steroid hormones are also excessively 
metabolized by 11β-HSD, 3α-HSD, 5α-/5β-reductase and 20α-/20β-HSD prior to excretion and are 
excreted only to a minor amount in their original biologically active form (Wudy et al., 2007). Selected 
potential follow-up reactions are shown in Figure 3.3 by taking 11β,18-diOH-OT as an example. The 
presented P450-dependent whole-cell system with E. coli, which enabled the transformation of OT by 
CYP11B2 in a preparative scale, can serve as source for the lead structures for further chemical or 
enzymatic modification to synthesize these alternative metabolites. Besides, combinatorial 
biotransformations of steroids in a single set up by all the enzymes mentioned represents a sophisticated 
approach to produce a set of derivatives, which are produced by the interplay of all enzymes 
contributing to human steroid biosynthesis and metabolism. Therefore, all enzymes of interest need to 
be present in the same conversion system, which can be realized by their co-synthesis in a single host 
cell. A recombinant strain of Saccharomyces cerevisiae expressing four steroidogenic P450s 
(CYP11A1, CYP11B1, CYP17A1 and CYP21A2), their redox partners AdR and Adx as well as a 3β-
HSD was established for the synthesis of cortisol from yeast membrane sterols (Szczebara et al., 2003). 
This example impressively demonstrates the functionality of multi enzyme cascades in microbial whole-
cell catalysis of steroids and an analog system expressing the aforementioned enzymes could deliver 
interesting new AAS metabolites. 
 
Figure 3.3: Putative enzymatic and non-enzymatic follow-up transformations of 11β,18-diOH-OT 
in humans. Modifications are highlighted and could be introduced by 5β-reductase and 3α-HSD (left), 
which are known to contribute to OT metabolism (Schänzer, 1996), 11β-HSD (middle), which 
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interconverts natural 11β-OH- and 11-keto- corticosteroids (Wudy et al., 2007) or by Wagner-Meerwein 
(WM) rearrangement to a 17β-hydroxymethyl-17α-methyl-18-norandrost-13-ene product (right).  
However, one might also argue that the total of product formation by the CYP11 family and 
consecutively the excreted amounts are below the detection limit. CYP11A1 is expressed in classical 
steroidogenic and a few other tissues like the skin and gastrointestinal tract, brain and immune system. 
CYP11B1 and CYP11B2 expression is even more restricted and limited to the respective zone of the 
adrenal cortex and the brain, where its function is still unclear (Erdmann et al., 1996). Their putative 
expression in the heart is controversial (Yoshimura et al., 2002; MacKenzie et al., 2012).  
In conclusion, the newly identified OT derivatives cannot directly serve as target analytes for doping 
conviction but are interesting intermediates for the synthesis of putative follow-up metabolites. A proof 
of their formation in humans remains to be established. Nevertheless, the detection of 11β-OH-
metandienone and 18-OH-metandienone, which were synthesized by purified CYP11B2 and by 
recombinant Schizosaccharomyces pombe, were detected in the urine after a single administration of 25 
mg metandienone (Parr et al., 2012). 18-OH metabolites were also found after administration of 
mesterolone, methenolone, and stenbolone (Masse and Goudreault, 1992). This makes a contribution of 
steroidogenic P450s to human in-vivo pharmacokinetics conceivable. Still, it has to be considered 
carefully that the formation of 11β-OH-testosterone by human liver microsomes (Choi et al., 2005) and 
the formation of 18-hydroxylated metabolites of C19 steroids by rat liver microsomes (Gustafsson and 
Lisboa, 1970) has been demonstrated. This hints at additional extra-adrenal sites of steroid 11β- and 18-
hydroxylase activity. 
3.1.3 Metabolism of pharmaceuticals by the CYP11B subfamily is limited to synthetic steroid 
derivatives. 
Besides AAS, the mineralocorticoid receptor antagonists spironolactone and canrenone were identified 
as new xenobiotic substrates for CYP11B1 and CYP11B2 during the investigations outlined in 
manuscript 2.4. The emerging products were to date unknown, but could be structurally identified in this 
work. 11β-OH-spironolactone, 18-OH-spironolactone and 19-OH-spironolactone are produced from 
spironolactone by both CYP11B isoforms. Canrenone is transformed to 11β-OH-canrenone and 18-OH-
canrenone by both isoforms and in addition to 11β,18-diOH-canrenone by only CYP11B2. Additionally, 
another AAS, methyltestosterone (17β-OH-17α-methyl-testosterone; MT), and the synthetic gestagen 
medroxyprogesterone (6α-methyl-progesterone, MP) could successfully be converted with reconstituted 
in-vitro systems of CYP11B1 and CYP11B2. HPLC chromatograms (Figures S1 and S2 in 5.2 
Supplemental data) revealed the formation of one major product for both substrates by CYP11B1 and 
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CYP11B2 and only minor side product formation, which is slightly higher for CYP11B2 as concluded 
from the peak area portion. The major products were identified as 11β-OH-MT by NMR (Table S1 in 
5.1.2) and 11β-OH-MP (also called medran) by comparison with the retention time of a commercially 
available standard in the HPLC measurements (Figure S1 in 5.2). Scheme S1 illustrates the respective 
biotransformations with structural formulas. OT remains the only xenobiotic steroid studied here, which 
was shown to undergo the complete reaction repertoire of CYP11B2 including an oxidation to the 18-
aldyhyde. This strengthens the hypothesis that the 3-keto-4-chloro-∆4 motif of OT allows an extended 
retention in the active site and processive oxidations. MT and MP also induced a high spin shift of the 
heme iron and Kd values were determined by difference spectroscopy (Figure S3 in 5.2). All values 
determined in this work are summarized in Table 3.1.    
Table 3.1: Summary of dissociation constants (Kd) determined in this work by difference 
spectroscopy. Values were determined as described in 2.3, 2.4 and Figure S4 by plotting the 
absorbance changes of the difference spectra against the ligand concentration and subsequent regression. 
For CYP11B2, a type-II-difference spectrum due to a low spin shift of the heme iron was observed upon 
the addition of stanozolol, while all other compounds induced a high spin shift as shown by the type-I-
difference spectrum. No spin shift changes could be observed for CYP11B1 when titrated with 
stanozolol indicated by (-). n.d.: not determined. For the comparison of the 2 CYP11B isoforms, the 
lower Kd indicating the higher affinity of the enzyme is highlighted in blue. 
 
 
 
 
 
 
 
 
 
Interestingly, MT and MP are the only exogenous steroids with a higher affinity for CYP11B1 than for 
CYP11B2. For MT, where only a slight difference is observed, this can be explained by the small 
Steroid Kd CYP11B1 
[µM] 
Kd CYP11B2 
[µM] 
DOC 8.1 ± 0.5 1.3 ± 0.1 • 
RSS 6.6 ± 0.4 n.d. 
B n.d. 115 ± 6 
OT 17.7 ± 2.2 5.4 ± 0.4 
Medroxyprogesterone 17.7 ± 2.2 50.2 ± 5.1 
Methyltestosterone 12.4 ± 0.6 18.0 ± 0.7 
Spironolactone 9.3 ± 0.7 4.1 ± 0.4 
Canrenone 74.5 ± 9 5.5 ± 0.4 
Stanozolol - 5.0 ± 0.3 
• (Hobler et al., 2012)    
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overall size of the molecule, which does not require a high degree of flexibility of the P450 to enable an 
efficient binding. In case of MP, affinity is almost three times higher for CYP11B1, which hints at an 
enhancing effect of the 6α-methyl group for the interaction of the steroidal α-face with the hydrophobic 
amino acids of the active site pocket (Strushkevich et al., 2013), which is more dominant in CYP11B1. 
As CYP11B2 turned out to be the generally more efficient catalyst for xenobiotic oxidation, a set of 
marketed non-steroidal drugs was tested for conversion with CYP11B2. Structures of these drugs are 
shown in Figure S4 (see 5.2). However, none of these substances was converted. In conclusion, the 
current experimental status suggests that the potential of the two human CYP11B subfamily members as 
metabolizers of xenobiotics is limited to synthetic steroid derivatives. The core structure, which is 
shared by all substrates, and permitted deviations are schematically represented in Figure 3.4. 
 
Figure 3.4: Schematic representation of the core structure of all CYP11B substrates and their 
variety. For the design of the scheme, the natural substrates RSS and DOC, all substrates discovered in 
this work, metandienone (Parr et al., 2012) as well as progesterone, testosterone and androstenedione 
(Strushkevich et al., 2013) were considered. 11β- and 18-hydroxylated reaction intermediates are not 
taken into account. The common steran scaffold shared by all substrates is highlighted in blue. Dashed 
bonds represent putative double bonds. Composition and stereochemistry of substituents are indicated. 
3.1.4 The consideration of steroidogenic P450s as drug metabolizers can improve drug safety 
testing. 
 
Synthetic derivatives of steroid hormones, which were identified in this study as substrates for selected 
steroidogenic P450s, are frequently applied pharmaceuticals for hormone replacement therapies and the 
treatment of various medicinal issues. Steroidal mineralocorticoid receptor antagonists are used as 
diuretics and for the treatment of hypertension and related diseases. AAS are abused for doping 
purposes as aforementioned, but a clinical application in burn injuries (Rojas et al., 2012) and several 
muscle-wasting diseases (Shahidi, 2001) is also indicated. Moreover, beneficial effects for the treatment 
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of postmenopausal osteoporosis (Andreopoulou and Bockman, 2015) and the rehabilitation of older 
people after severe surgeries (Farooqi et al., 2014) are discussed. Glucocorticoids are potent anti-
inflammatory and immunosuppressive drugs. Clinically applied ones are for example the major human 
glucocorticoid cortisol itself and the synthetic products premedrol and medrol (methylprednisolone). 
Synthetic gestagens (also termed “progestines”) are used as contraceptives, whereby they can be 
combined with estrogens (Dewick, 1999), and for the treatment of endometriosis. MP is a synthetic 
gestagen, which was never marketed, but is excessively formed during the metabolism of 
medroxyprogesterone-17α-acetate (Ishihara et al., 1976), which is included in the List of Essential 
Medicines of the World Health Organization (World Health Organization, 2015). This work shows the 
potential of CYP11B1 and CYP11B2 to catalyze the conversion of compounds from different classes of 
steroidal pharmaceuticals: Anabolics, aldosterone antagonists and gestagens. Due to the large variety of 
derivatives available for pharmaceutical applications, many more new CYP11B substrates can be 
expected to be found in the near future.  Consequently, the “critical role” (Guengerich et al., 2005), 
which is demanded for the functional classification of human P450s into different substrate categories, is 
established. A critical role in xenobiotic metabolism can be attributed to an enzyme, if the rate of 
oxidation is high enough to be considered as significant in the in-vivo metabolism and the 
biotransformation has a biological effect and might be critical to health. A demonstration of the critical 
role is provided by this work on both levels: Firstly, relevant binding affinities and catalytic rates are 
reported for different synthetic substrates by characterization on enzymatic level. Secondly, altered 
pharmacodynamic properties of the emerging metabolites are shown for spironolactone and canrenone, 
whose CYP11B-derived products vary in their antagonistic properties for the MR compared to the 
parent compounds (see manuscript 2.4). In summary, the results strongly suggest the consideration of 
steroidogenic P450s as drug-metabolizers and consecutively the consideration of emerging metabolites 
in drug metabolite safety testing for the elucidation of putative adverse effects. Thereby, especially 
cross-reactivity with other steroid hormone receptors is relevant. Alterations of the effects on the MR by 
11β- and 18-hydroxylation were already shown for spironolactone and canrenone (2.4). Moreover, it is 
of particular interest to analyze the CYP11B-derived products for cross-activation of the glucocorticoid 
receptor (GR), whose activation depends on the formation of a hydrogen bond with an 11β-OH group of 
the steroidal ligand in addition to H-bonding involving a 21-OH, a 20-keto and a 17α-OH function 
(Bledsoe et al., 2002; Kauppi et al., 2003). In case of both, MR and GR, the tissue-specific expression 
pattern overlaps with the expression patterns of CYP11B1 and CYP11B2, which are, besides in the 
adrenal, also expressed in the brain and putatively in the heart. MR expression is reported for the 
epithelial target tissues of kidney, parotid and colon, but also for the hippocampus and heart (Funder et 
al., 1988; Zennaro et al., 1997). GR is expressed in the brain, skeletal muscle, lung kidney, liver, heart, 
colon, nasal mucosa, macrophages, eosinophils, peripheral blood mononuclear cells and neutrophils 
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(Pujols et al., 2002). The co-localization of enzyme and receptor points towards an autocrine or 
paracrine influence of CYP11B metabolism and, therefore, possible tissue-specific adverse effects. For 
the androgen, estrogen and progesterone receptors an impairment of ligand binding by CYP11B-derived  
metabolites can be expected, which will reduce the efficiency of administered compounds targeting 
these receptors, as the ligand binding pocket is aligned by mainly hydrophobic residues (Brzozowski et 
al., 1997; Williams and Sigler, 1998; Sack et al., 2001). However, for the evaluation of possible effects 
sufficient amounts of the novel metabolites need to be made available.  
 
3.2 Biotechnological relevance of the CYP11B1- and CYP21A2-dependent E. coli catalysts 
3.2.1 The developed biocatalysts exhibit relevant productivities for industrial glucocorticoid 
production. 
The application of mammalian steroidogenic P450s in biotechnology is of great interest for different 
purposes. Their newly established role as metabolizers of (steroidal) drugs leads to a demand of their 
metabolites for bioactivity/toxicity testing and as authentic analytical standards for periodical calibration 
as made compulsory by the instructions of i.e. Good Laboratory Practice and Good Manufacturing 
Practice. Furthermore, due to their outstanding selectivity, steroidogenic P450s are attractive 
biocatalysts for the production of steroidal pharmaceuticals and many efforts have been made to date to 
realize and optimize their application. CYP11A1 can be used for the production of pregnenolone, the 
precursor for further functionalizations, from cholesterol as well as plant and fungal sterols and was 
recently made accessible for whole-cell conversion in Bacillus megaterium (Gerber et al., 2015). 
Subsequently, especially the employment of CYP11B1, CYP17A1 and CYP21A2 is desirable, because 
they catalyze the hydroxylations that are essential for the activation of the glucocorticoid receptor 
(Bledsoe et al., 2002; Kauppi et al., 2003) and thereby the commercially relevant anti-inflammatory and 
immunosuppressive effects. For the application of CYP11B1 and CYP21A2, several yeast-based 
systems have been developed (Dumas et al., 1996; Dragan et al., 2005; Hakki et al., 2008; Zehentgruber 
et al., 2010) and even a combinatorial system including CYP11A1 and CYP17A1 for the synthesis of 
cortisol from membrane ergosterol was established (Szczebara et al., 2003). The bacterial systems 
presented in this work with E. coli significantly outcompete these eukaryotic systems with efficiencies 
of 0.84 g cortisol *L-1*d-1 and 0.65 g premedrol *L-1*d-1. These productivities fit into the operational 
window defined for P450 processes in the industry, but are still at the lower limit (Straathof et al., 2002; 
Julsing et al., 2008). Major reasons of the limitations are the membrane-associated nature of the applied 
P450s, which complicates their expression in prokaryotes, and the generally low activity of 
steroidogenic P450s, which has evolved along with their biosynthetic function. The highest reaction 
3. Discussion 
 
126 
 
velocity of a P450 reported to date is 363 s-1 for a mutant of the bacterial CYP102A1 (BM3) (Eiben et 
al., 2006). Human CYP11B1 and bovine CYP21A2, which were investigated in this work, exhibit 
respective maximal velocities of 1.6 s-1 for the formation of cortisol from RSS (this work, Figure S5 in 
5.2) and in the range of 0.7 s-1 for the 21-hydroxylation of progesterone and 17-OH-progesterone (Pallan 
et al., 2015). Therefore, engineering of the biocatalysts is required to identify and overcome the 
bottlenecks of product formation. During the optimization of the CYP11B1- and CYP21A2-expressing 
whole-cell systems, presented in the scientific contributions 2.1 and 2.2, engineering on 2 levels of the 
P450 biocatalysts was successfully performed. First, engineering on the level of the P450 was conducted 
by molecular evolution and screening for enhanced product formation, wherefrom several CYP11B1 
variants with enhanced activity emerged (see 2.1). Second, the electron transfer system was engineered 
by quantitative and qualitative approaches with the enhancement of Adx expression (see 2.1) and the 
replacement by heterologous redox partners (see 2.2). Gained insights are transferable to other P450s 
and, hence, of general relevance for the optimization of P450 biocatalysts. The transferability of both 
aspects will be discussed in the following sections. 
3.2.2 Selected CYP11B1 mutations can set a basis for the rational design of other P450 catalysts. 
Selected expression or activity improving mutations discovered in the CYP11B1 library and described 
in 2.1 can be used for the optimization of the other biotechnologically interesting steroidogenic P450s 
by SDM as concluded from the primary sequence alignments shown in Figure 3.5 A. A replacement, 
analogous to the N-terminal G to R replacement in CYP11B1 (G23R), which was demonstrated to 
significantly increase the expression level in E.coli, is promising to comparably enhance the expression 
of CYP17A1 and CYP21A2, whose wildtype sequences encode non-charged amino acids in the 
respective positions. Respective exchanges are S33R for CYP17A1 and G36R for CYP21A2. This idea 
is supported by the fact that modifications of the N-terminus including single amino acid exchanges, 
sequence replacement and truncations of hydrophobic parts appear as the key to the expression of 
eukaryotic P450s in bacteria (Gillam, 2008). The occurrence of the other mutations (except for L271M) 
in the center of helices of the conserved P450 folding (E, I and J, see Figure 3.5 A) makes them more 
likely to have general beneficial effects on P450 function than only CYP11B1-specific effects. 
Especially the transferability to CYP11A1, which has a common evolutionary ancestor with the 
CYP11B subfamily (Nelson et al., 2013), becomes evident from the sequence alignment. CYP11A1 
encodes the same amino acids as CYP11B1 in the respective positions aligned to H171 and L271 of 
CYP11B1. The same exchanges (H→L and L→M) as observed to be beneficial for CYP11B1 activity 
are thus interesting candidates for CYP11A1 SDM. The threonine residue of CYP11A1 aligned to 
position 286 of CYP11B1 represents another interesting mutagenesis spot. Figure 3.5 B shows in detail 
the localization of this position in the CYP11B1 model in the I-helix. Its proximity to the conserved 
3. Discussion 
 
127 
 
acid/alcohol-pair (D294/T295), which is essential for proton transfer and progression of the catalytic 
cycle (Figure 1.2 A), suggests that the selected mutation contributes to these processes and thereby 
promotes substrate hydroxylation or prevents of ROS formation. Saturation mutagenesis of position 286 
and the neighboring ones can help to further elucidate this aspect. As there is very limited information in 
the literature about mutational strategies to improve P450s activity, which are not primarily motivated 
by an improvement of the selectivity, the identification of crucial residues is of considerable value to 
develop strategies for rational enzyme engineering.  
 
Figure 3.5: Localization of CYP11B1 activity enhancing mutations and alignment with other 
P450s. (A) – Alignment of selected sequence parts of CYP11B1 with other steroidogenic P450s. 
Sequences were extracted from uniprot.org (bovine CYP11A1: P00189; bovine CYP17A1: P05185; 
bovine CYP21A2: P00191). The CYP11B1 sequence is shown as modified for expression in E. coli 
(Zöllner et al., 2008). The alignment was done with the Clustal Omega tool 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). Relevant helical structures are indicated as in the latest 
CYP11B1 homology model (Hobler, 2013). (B) Extract of the CYP11B1 homology model showing 
M286 and the conserved acid-alcohol pair in element color-coded stick representation in the I-helix 
(cartoon representation) above the heme.  
3.2.3 A combination of Arh1 and adjusted Adx expression leads to a versatile redox system for 
P450 whole-cell application. 
The efforts made in publication 2.1 to improve the activity of the CYP11B1 biocatalyst revealed Adx 
expression as a limiting factor, which could successfully be overcome by the introduction of additional 
cDNA copies of Adx into the polycistronic expression plasmid. The presented strategy to improve P450 
activity by enhancing Adx expression in the whole-cell catalyst is as well transferable to other P450 
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systems, as Adx can also transfer electrons to bacterial and class II P450s (Ewen et al., 2012). Because 
of its soluble nature and small size of ~14 kDa it is easy to be synthesized in high levels by E. coli by 
simply enhancing its mRNA level. A dependency of P450 activity on Adx concentration is generally 
accepted, as the electron transfer from Adx to the P450 is known as a rate-limiting step (Cao and 
Bernhardt, 1999; Guengerich, 2002). Enhancing its expression is thus a very straight-forward strategy 
and can be advantageous over the artificial construction of self-sufficient P450-redox partner fusions, 
which are likely to facilitate the final electron transport step, but whose design and expression are 
challenging (Munro et al., 2007). The presented unique polycistronic approach still enables the 
expression of all constituents of the redox system from one plasmid and requires only a single antibiotic. 
It is, therefore, well suited for up-scaling of the reaction volume towards industrial standards in contrast 
to approaches, which regulate the expression ratio of different genes by the employment of different 
plasmids, which need additional costly antibiotics to be stably maintained. The replacements of the 
autologous redox system of CYP21A2 by heterologous ones for the optimization of the whole-cell 
activity impressively demonstrate the possibility to support one P450 by versatile combinations of redox 
proteins from different organisms and classes (see publication 2.2). Arh1 from Schizosaccharomyces 
pombe was identified as the most efficient reductase due to its soluble character and capability to accept 
NADH in addition to NADPH. The use of Arh1 in a plasmid with several copies of Adx would be the 
next step of engineering the redox system to combine the qualitative and quantitative optimizations. This 
mixed system can efficiently supply a large variety of P450s in whole-cell systems. Its application for 
the screening of orphan P450s with unknown redox partners for novel reactions is, therefore, 
recommended. Current DNA sequencing technologies deliver genomic sequence information at a 
steadily increasing rate and their bioinformatic evaluation leads to the identification of new P450s. A 
screening of substrate libraries with the new P450s in combination with the redox system constituted of 
Arh1 and Adx at the adjusted expression level can reveal novel reactions with biotechnological 
relevance.   
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4. Outlook 
This work demonstrates the capability of steroidogenic P450s and among them the CYP11B subfamily 
in particular to convert xenobiotic steroids from different classes with relevant catalytic rates. This raises 
the question, how far their substrate spectrum can be extended and motivates a systematic search for 
additional substrates. For the screening of substrate libraries, a whole-cell approach with the CYP11B1- 
or CYP11B2-expressing E. coli cells employed in this work is well-suited when it is down-scaled to a 
microtiter plate format as it enables a time- and cost-efficient analysis. For both CYP11B isoforms 
expression systems in 1-mL scale are available and were shown to mimic the full catalytic potential of 
the purified enzymes. Therefore, these systems are promising tools for the identification of new 
substrates. CYP11B1 and CYP11B2 have been ascertained to be highly polymorphic (Bernhardt and 
Waterman, 2007; Schiffer et al., 2015). Several polymorphisms have to date been cloned and 
demonstrated to exhibit altered activities in-vitro (reviewed by (Schiffer et al., 2015)). It is, therefore, of 
interest to study the metabolism of the new pharmaceutical substrates by P450s displaying different 
polymorphisms and consider the results in combination with the adverse effects that might emerge from 
the products, i.e. the reduction of the MR antagonist properties of spironolactone by CYP11B1- and 
CYP11B2-dependent conversion. Within the model of personalized medicine, these insights into the 
relation between polymorphisms and the emergence of adverse effects can help to improve drug usage 
and dosage for the benefit of the patient. However, to study putative adverse effects of metabolites 
formed by CYP11B1 and CYP11B2, sufficient amounts need to be supplied. The recombinant E. coli 
system, which was used in this study under non-optimized conditions, is a promising basis for the 
optimization of metabolite production and the major products were already successfully produced for 
purification in low mg amounts. Nevertheless, the production of minor metabolites in appropriate 
amounts can be problematic. Therefore, the selectivity of the CYP11B isoforms can be modulated by 
rational design. Combinatorial randomization of the active site residues interacting with the steroid α-
face (W116, F130 and F487 in CYP11B2) with a reduced amino acid alphabet that maintains the 
aromatic nature (F, W, Y) could be used to alter substrate binding in a way, which favors 18- and 19-
hydroxlation. To target C19, SDM following a structural alignment with CYP19A1, which catalyzes 
successive hydroxylations at C19 position for its substrates, is an interesting approach. For an 
enhancement of 18-hydroxylase activity, a sequence comparison with the CYP11B3 isoform from rat, 
which has a preference for 18- over 11β-hydroxylase activity (Zhou et al., 1995), could give helpful 
information for possible SDM.  
Regarding the engineering of CYP11B1 for the biotechnological production of glucocorticoids by 11β-
hydroxylation, detailed in-vitro studies of the effect of the selected mutations on parameters of 
4. Outlook 
 
130 
 
CYP11B1 activity should be performed (i.e. the determination of kinetic parameters kcat and KM in 
dependency on substrate and Adx concentration, substrate binding, thermostability, solvent tolerance) to 
understand the underlying structure-function relationship and to establish a rational basis for a second 
mutant generation.  
The discovery of medroxyprogesterone as new substrate for CYP11B1, which is selectively 11β-
hydroxylated (Figure S1 in 5.2, D) in E. coli, opens up a new synthetic path for the direct production of 
premedrol from medroxyprogesterone with a single biocatalyst expressing CYP11B1 and CYP21A2. As 
both P450s accept Adx as redox partners, a single electron transfer chain constituted of Arh1 and Adx at 
a suitable level, which can be regulated as aforementioned, can supply both enzymes. This potential E. 
coli biocatalyst is illustrated in Figure 3.6. However, it has to be mentioned that the balanced co-
expression of two P450s and their redox partners will be a challenging task. Alternatively, the desired 
cascade reaction could be realized by co-cultivation of two strains expressing either P450. 
 
 
Figure 3.6: Schematic representation of an E. coli-based biocatalyst for the one-pot-synthesis of 
premedrol from medroxyprogesterone by CYP11B1 and CYP21A2. Electron transfer can be 
ensured by co-expression of Arh1, which uses NADH and NADPH as electron source, and Adx, whose 
expression level can be increased to its optimum by adjusting its cDNA copy number. 
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5. Appendix 
 
5.1 Supplemental methods 
5.1.1 OT administration study and screening for CYP11B-derived metabolites 
The OT administration study and post-administration analysis of urine were performed by the Center for 
Preventive Doping Research, Prof. Dr. Mario Thevis, German Sport University, 50933 Cologne, 
Germany. A single dose of 5 mg OT was orally administered by a male subject without further 
medication, urine was periodically sampled and stored at -20 °C until analysis (Tretzel et al., 2015). 
Urine analysis and screening  for 11β-OH-OT, 11β,18-diOH-OT and 11β-OH-OT-18-al were performed 
by liquid chromatography-tandem mass spectrometry, including triple quadrupole mass spectrometry 
and high-resolution/high-accuracy mass spectrometry, and gas chromatography-tandem mass 
spectrometry as described previously (Guddat et al., 2013).    
5.1.2 NMR spectroscopy of 11β-OH-methyltestosterone 
After whole-cell biotransformation of methyltestosterone with CYP11B2 as described in 2.3 and 2.4 the 
major product was purified by RP-HPLC and analyzed by NMR spectroscopy. NMR measurements 
were performed by Dr. Josef Zapp (Department of Pharmaceutical Biology) and the results were 
evaluated by Dipl.-Chem. Martin Litzenburger (Institute of Biochemistry). 1H and 13C NMR were 
recorded on a Bruker (Rheinstetten, Germany) 500 NMR spectrometer. Two-dimensional NMR spectra 
were recorded as gs-HHCOSY, gs-HSQC, and gs-HMBC. All chemical shifts are relative to CDCl3 (δ = 
77.00 for 13C-NMR; δ = 7.24 for 1H-NMR) using the standard δ notion in parts per million. The spectra 
showed signals for an additional secondary hydroxyl group (δH 4.41 m; δC 68.30), which could be 
located at C-11. Its proton showed correlations to H-9 (δ 0.94, dd) and H-12a (δ 1.53, dd) and H-12b (δ 
1.65, dd). Thereby, H-11 must be in equatorial position due to its small coupling constants to H-9 (J= 
3.5 Hz) and H-12 (J= 3.5) as well as coupling with both H-1 in the 2D-NMR measurements and is 
therefore in α-orientation. Consecutively, the hydroxyl at C-11 is β-orientated. The following Table S1 
summarizes all chemical shifts in parts per million and coupling constants assigned to the respective 
carbon atoms numbered according to standard steran scaffold numbering. 
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Carbon number 1H NMR coupling constants [Hz] 13C NMR 
1 1,80-1,87 m (1H) +  
2,15-2,21 m (1H) 
 34,94 
2 2,30-2,37 m (1H) +  
2,42-2,50 m(1H) 
 33,83 
3 -  199,53 
4 5,65 d (1H) 1,7 122,32 
5 -  172,16 
6 2,19-2,24 m(1H) + 
2,42-2,50 m(1H) 
 32,05 
7 0,98-1,05 m (1H) + 
1,95-2,02 m(1H) 
 32,39 
8 1,97-2,04 m(1H)  32,48 
9 0,94 dd (1H) 11,1; 3,5 56,32 
10 -  39,28 
11 4,41 m (1H)  68,30 
12 1,53 dd (1H) + 
1,65 dd (1H) 
 
3,5; 13,7 
41,07 
13 -  44,52 
14 1,12-1,18 m (1H)  51,70 
15 1,37 dd (1H) + 
1,59-1,65 m (1H) 
 23,28 
16 1,69-1,77 m (1H) + 
1,80-1,87 m (1H) 
 38,79 
17 -  81,85 
18 1,14 s (3H)  16,53 
19 1,44 s (3H)  20,87 
20 1,16 s (3H)  25,89 
NOESY crosspeaks 4,41 m (1H) 1,83;  2,17  
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5.2 Supplemental data 
 
Fig. S1: HPLC chromatograms of CYP11B1- and CYP11B2-dependent conversion of 
medroxyprogesterone. Steroids were separated on a reverse phase column with an acetonitrile/water 
gradient and monitored at 240 nm, whereby standards of medroxyprogesterone (black line) and 11β-
OH-medroxyprogesterone (blue line) showed retention times of 20.4 min and 15.9 min, respectively 
(A). Conversions of medroxyprogesterone by CYP11B1 (B) and CYP11B2 (C) were conducted in-vitro 
with purified enzymes as described in 2.3 (Schiffer et al. 2015b) and yielded in the formation of 11β-
OH-medroxyprogesterone and a minor product (RT 14.6), which is formed to a greater extent by 
CYP11B2. The negative control (grey line) was incubated without NADPH. E. coli based whole-cell 
conversion of 250 µM medroxyprogesterone with CYP11B1 as described in 2.1 (Schiffer et al. 2015a) 
enabled the production of 11β-OH-medroxyprogesterone without significant formation of minor 
products with a volumetric productivity of 54 mg*L-1*d-1 as calculated from peak area portions in the 
HPLC chromatogram after 24h of conversion (D). 
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Fig. S2: HPLC chromatograms of CYP11B1- and CYP11B2-dependent conversion of 
methyltestosterone. Steroids were separated on a reverse phase column with an acetonitrile/water 
gradient and monitored at 240 nm, whereby methyltestosterone showed a retention time of 18.4 min (A). 
Conversions of methyltestosterone by CYP11B1 (B) and CYP11B2 (C) were conducted in-vitro with 
purified enzymes as described under 2.3 (Schiffer et al. 2015b) and lead to the formation of the major 
product 11β-OH-methyltestosterone (RT 12.6 min; see Table S1 for structural identification by NMR) 
and a minor product (RT 9.9 min) in case of CYP11B2. Additional putative minor products are marked 
by arrows. The negative control (grey line) was incubated without NADPH.  
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Scheme S1: Structural formula of the CYP11B1- and CYP11B2-dependent conversion of 
medroxyprogesterone (A) and methlytestosterone (B). The 11β-hydroxylation of 
medroxyprogesterone was identified by HPLC analysis and comparison of the retention time with a 
commercially available standard. 11β-OH-methyltestosterone was identified by NMR spectroscopy as 
described in Table S1.  
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Fig. S3: Determination of dissociation constants for CYP11B1 and CYP11B2 by difference 
spectroscopy. Difference spectroscopy was performed as described in 2.3 (Schiffer et al. 2015b) (A) 
CYP11B1 with medroxyprogesterone, (B) CYP11B2 with medroxyprogesterone, (C) CYP11B1 with 
methyltestosterone, (D) CYP11B2 with methyltestosterone, (E) CYP11B2 with stanozolol. No effect on 
the spin state equilibrium was observed for CYP11B1 upon titration with stanozolol up to 200 µM. 
Peak-to-trough (∆Amax-min) were plotted against the ligand concentration and dissociation constants were 
determined by hyperbolic regression for B (R2 0.990) or regression by tight binding equation for A (R2 
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0.985), C (R2 0.998), D (R2 0.999) and E (R2 0.995). Values represent the mean of three titrations with 
standard deviation. Resulting constants are summarized in Table 3.1. 
 
 
Fig. S4: Structural formula of drugs assayed for metabolism by CYP11B2. (1) amitriptyline – 
antidepressant; (2) papaverine- antispasmodic drug; (3) diclofenac – analgesic; (4) diltiazem – calcium 
antagonist; (5) haloperidol – neuroleptic; (6) olanzapine – neuroleptic; (7) quinine – antipyretic, 
analgesic, anti-malaria; (8) tamoxifen – selective estrogen receptor modulator; (9) chlorpromazine – 
neuroleptic; (10) carbamazepine  - anticonvulsive. 200 µM of each compounds were incubated with a 
reconstituted CYP11B2 system as described in 2.3 (Schiffer et al. 2015b) for 3-4 h. Extraction and 
HPLC analysis were performed with compound specific protocols and detection wavelengths. For none 
of the drugs a conversion by CYP11B2 was observed.  
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Fig. S5: Steady-state kinetics of CYP11B1-dependent conversion of 11-deoxycortisol to cortisol. 
Reactions were performed in a reconstituted in-vitro system with purified enzymes in the presence of an 
NADPH regeneration system as described in 2.3 (Schiffer et al. 2015b). Enzyme concentrations were 
0.25 µM for CYP11B1 and human AdR and 5 µM for human Adx. Reactions took place at 37 °C and 
750 rpm and were stopped after 1-4 minutes under steady-state conditions. Progesterone was added as 
internal standard and samples were extracted with chloroform. Cortisol formation was quantified by 
HPLC analysis with an acetonitrol/water gradient and detection at 240 nm with a standard curve. 
Reaction velocity was plotted against the substrate concentration and kinetic parameters were 
determined by hyperbolic regression according to Michealis-Menten.   
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5.3 Abbreviations and units 
 
AAS Anabolic androgenic steroids 
Andro Androstenedione 
AdR Adrenodoxin reductase 
Adx Adrenodoxin 
Aldo Aldosterone 
AR Androgen receptor 
Arh1 Adrenodoxin reductase homologue 1 
B Corticosterone 
CPR Cytochrome P450 reductase 
d Day 
DHEA Dehydroepiandrosterone 
DOC 11-deoxycorticosterone 
E. coli Escherichia coli 
ER Endoplasmic reticulum 
FAD Flavin adenine dinucleotide 
FDA Food and drug administration 
FdR Ferredoxin reductase 
Fdx Ferredoxin 
FMN Flavin mononucleotide 
g Gram 
GR Glucocorticoid receptor 
h Hour 
HPLC High performance liquid chromatography 
HSD Hydroxy steroid dehydrogenase 
Kd Dissociation constant 
L Liter  
LC Liquid chromatography 
LTM Long-term metabolite 
m Meter 
ME Molecular evolution 
M Molar 
MP Medroxyprogesterone 
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MR Mineralocorticoid receptor 
MRA Mineralocorticoid receptor antagonist 
MS Mass spectrometry 
MT 17α-Methyltestosterone 
NAD(P)H Nicotinamide adenine dinucleotide (phosphate) 
n.d. Not determined 
OT Oral-turinabol 
P450 Cytochrome P45 
Preg Pregnenolone 
Prog Progesterone 
ROS Reactive oxygen species 
RSS Reichstein’s substance S, 11-deoxycortisol 
s Second  
SDM Site directed mutagenesis 
Testo Testosterone 
UV Ultra violett 
WADA World Anti-Doping Agency 
WM Wagner Meerwein 
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Abbreviations for amino acids 
A Alanine M Methionine 
C Cysteine  N Asparagine 
D Aspartate P Proline 
E Glutamate  Q Glutamine 
F Phenylalanine R Arginine 
G Glycine S Serine 
H Histidine T Threonine 
I Isoleucine V Valine 
K Lysine W Tryptophane 
L Leucine Y Tyrosine 
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